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SUMMARY 
 
Cryptococcal meningitis is an important opportunistic infection in immunocompromised patients. It has 
been well established that a distinguishing feature of this form of meningitis is a relatively low 
neutrophil count in the cerebrospinal fluid (CSF) compared to bacterial meningitis. There has been 
speculation and research undertaken previously to understand this phenomenon, however, little 
information is available in human studies. Furthermore, there is insufficient information on expression 
and function of Toll-like receptors (TLR) in the human central nervous system (CNS). The work 
presented here investigated the effect of the capsular material of a series of clinical isolates of 
Cryptococcus neoformans on neutrophil recruitment at the site of infection and determined whether 
downregulation occurs at the level of TLR expression. This was done in a multiple component study.  
Clinical information was collected from patients with cryptococcal meningitis and baseline blood and 
CSF investigations were performed, which included the quantification of neutrophils in CSF and blood 
specimens. The size of the Cryptococcus capsule was measured in each isolate and shed capsular 
material was quantified in individual CSF specimens. The extent of neutrophil chemotaxis inhibition 
by individual strains of C. neoformans was determined by using a Transwell migration assay. Toll-like 
receptor (TLR)2 and TLR4 gene expression induced by individual C. neoformans isolates in human 
microglial cells was quantified. The possible associations among these experiments were subsequently 
evaluated. 
As anticipated, a paucity of neutrophils in the CSF was observed. The cryptococcal capsule was larger 
in isolates of patients with lower CSF neutrophil counts. In addition, patients with lower CSF neutrophil 
counts shed more capsular material in the CSF. Chemotaxis inhibition occurred in close to 70% of tested 
isolates. The concentration of shed capsular material in this group was higher compared to the group 
with no chemotaxis inhibition. Patients presenting with fever had higher CSF neutrophil counts as well 
as elevated intracranial pressures. The majority of isolates expressed downregulation for TLR2 and 
TLR4 in microglial cells exposed to C. neoformans. CSF neutrophil counts were lower in this group.  
These findings imply that the capsular components of C. neoformans downregulated recruitment of 
neutrophils into the CSF. Downregulation of neutrophil recruitment was observed at the level of TLR 
expression.
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CHAPTER 1 – INTRODUCTION 
 
1.1 Background and Research Rationale 
 
 
Cryptococcus neoformans is a facultative intracellular pathogen. This fungal pathogen is known to 
cause meningitis in the immunocompromised patient. The capsule of Cryptococcus neoformans is an 
established virulence factor. It has been shown previously that the cryptococcal capsule can change in 
size in response to environmental conditions [1, 2]. 
 It is well known that a characteristic of cryptococcal meningitis is the relatively low number of 
leucocytes in the CSF as compared to bacterial meningitis [3-5]. This is associated with a protracted 
versus an acute clinical presentation. The presence of leucocytes is regulated through chemotaxis. 
Chemotaxis is dependent on chemokine production at the site of infection and the level of expression 
of corresponding chemokine receptors on the migrating cells. Chemokines are produced when TLRs on 
cells at the infection site recognize specific microbes. For C. neoformans, TLR2 and TLR4 have been 
identified as important TLRs [6-8]. TLR2 and TLR4 are membrane protein receptors that are expressed 
on certain cell surfaces and together with CD14 are able to recognize various microbial products. When 
these receptors are activated, signaling cascades are triggered which result in a proinflammatory 
response [8]. While it is evident that TLR expression is significant, there is not much published 
information on TLR expression and function in human CNS glial cells [7].  
High levels of the cryptococcal capsular components glucuronoxylomannan (GXM), 
galactoxylomannan (GalXM), mannoprotein (MP)-1, and MP-2 in the CSF and blood of affected 
patients are a characterististic feature of disseminated cryptococcosis [3]. Some of these components 
have been shown to be involved in chemotaxis inhibition.  
Endothelial cells, astrocytes, and mononuclear cells are activated by TNF- and IL-1 to produce IL-8 
in the brain of patients who have meningitis [3]. IL-8 is a strong chemoattractant for polymorphonuclear 
leucocytes (PMNs). However, in cryptococcal meningitis, there is a paucity of PMNs in the CSF. 
Previous studies have shown that neutrophil migration  does not occur in the presence of GXM because 
of the absence of a chemotactic gradient across the blood brain barrier [5]. 
In this study, I hypothesized that the crytpococcal capsular material interferes with neutrophil 
chemotaxis and that the level of chemotaxis inhibition is related to severity of disease. In order to 
prevent cryptococcosis, one requires a functional innate immune response followed by an acquired 
immune response if this is not successful.  
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1.2 Aims 
 
 
1.2.1 To investigate the quantitative effect of the cryptococcal capsular material on neutrophil      
recruitment at the site of infection.  
1.2.2 To investigate whether downregulation of neutrophil chemotaxis occurs at the level of TLR 
expression.  
 
 
1.3 Objectives 
 
 
1.3.1 Obtain clinical information from patients with cryptococcal meningitis. 
1.3.2 Quantify the number of neutrophils in the CSF and blood. 
1.3.3 Measure the thickness of the cryptococcal capsule in each isolate. 
1.3.4 Determine the concentration of cryptococcal capsular material in individual CSF and serum 
samples by using antibodies against capsular components. 
1.3.5 Determine the extent of inhibition of neutrophil chemotaxis by individual strains of C. 
neoformans. 
1.3.6 Quantify the TLR2 and TLR4 expression induced by individual strains of C. neoformans in 
human microglial cells. 
1.3.7 To investigate possible associations between 1.3.1.and 1.3.2 with 1.3.3 to 1.3.6. 
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CHAPTER 2 – LITERATURE REVIEW 
 
2.1 A Brief History of the Organism Cryptococcus neoformans 
 
2.1.1 Nomenclature and Classification 
 
 
The genus Cryptococcus belongs to the basidiomycetous fungi and includes two species that are known 
to cause human disease, C. neoformans and C. gattii. In mammals, these pathogens can exist as 
intracellular yeasts, where they are found freely in tissue and body fluids or they may be enclosed by 
phagocytic cells, whilst in the environment, they can grow either freely or in soil amoeba [9, 10]. During 
the mid-twentieth century, scientists used rabbit antisera and defined four capsule serotypes (A – D) [9, 
11, 12]. This categorization has been refined over the years by various analyses including DNA 
sequencing, epidemiology and ecology among a few methods. There are two species in the current 
classification: C. neoformans, var. grubii (serotype A) and var. neoformans (serotype D) and C. gattii 
(serotypes B and C) [9, 13]. A further eight major molecular types: VNI and VNII (var. grubii), VNIV 
(var. neoformans), VNIII (AD hybrids), and VGI – VGIV (C. gattii) occur within the two species [9, 
14-17]. The genomes of these species have diverged more than 34 million years ago thus revealing 
species that have distinct ecological and pathological differences [9, 18]. The species names of the 
genus Cryptococcus still remains controversial. In a recent perspective by Hagen, et al, they discussed 
the advantages of recognising seven species within the genus rather than two species complexes, which 
would enhance further research into their possible differences [19]. C. neoformans is saprophytic in 
nature and is distributed worldwide. It has been associated with bird droppings (especially pigeon 
droppings), decaying vegetables and soil [20]. Although C. neoformans  changes from yeast to hyphae 
during its sexual cycle, some do not consider it to be a dimorphic fungus because of its predominant 
yeast form both outside and within the human host [21]. C. neoformans is an important cause of 
opportunistic infections in the immunocompromised patient whereas C. gattii  mainly affects 
immunocompetent individuals [20]. C. gattii has predominantly been found in tropical and subtropical 
areas and is associated with certain species of trees, particularly the eucalyptus tree and is also less 
responsible for human disease [22].  
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2.1.2 Cryptococcal Disease: Epidemiology and Infection 
 
 
Prior to the onset of the Acquired immune deficiency syndrome (AIDS) pandemic, cryptococcal 
infection was not considered a very common disease entity. There were less than 300 reported cases of 
cryptococcosis globally during the 1950s [9, 23]. As Human immuno-deficiency virus (HIV) became 
more prevalent during the following years, a distinct rise in cryptococcosis became evident. During the 
mid-1980s, the incidence of disease significantly increased with HIV/AIDS accounting for greater than 
80% of cases of cryptococcosis worldwide [24, 25]. Subsequent widespread implementation of 
antiretroviral therapy (ART) during the mid-1990s significantly reduced the incidence of HIV-
associated cryptococcosis in most developed countries, although the incidence in other at-risk 
populations did not change [25, 26]. Furthermore, in settings, where access to health care resources as 
well as access to ARTs is limited, for example, in sub-Saharan Africa and certain parts of Asia, the 
prevalence of cryptococcal meningitis remains high [25]. Mortality rate had actually peaked at 
approximately 600 000 deaths per year at the beginning of the twenty first century [27]. An estimated 
957 900 cases of meningoencephalitis was shown to have occurred every year globally, which resulted 
in more than 600 000 deaths per year [27]. In 2006, sub-Saharan Africa was found to have the most 
estimated cases (720 000 cases) followed by South and Southeast Asia (120 000 cases) [27]. It has been 
estimated that at least 222 000 HIV infected patients present with  cryptococcal meningitis throughout 
the world annually [28]. This in turn results in 181 000 deaths every year, of which the majority of cases 
occur in sub-Saharan Africa [28]. A recent study has implied that cryptococcosis remained the second 
commonest cause of AIDS-related mortality, and this is only narrowly overtaken by tuberculosis [28].  
Cryptococcal meningitis usually occurs in people with impaired cell-mediated immunity and is an 
important AIDS-related opportunistic infection. A large majority of cases are found in AIDS patients 
whose CD4 counts drop to less than 100 cells per microliter (cells/μl) [25]. The remaining cases are 
found in patients with haematological malignancies and transplant patients who are receiving 
immunosuppressive therapy [29]. Cryptococcal infection in general can be acute, chronic, or even 
asymptomatic. Generally, a pulmonary infection initially occurs which may spread systemically and 
ultimately infects the CNS [20]. Most cases of pulmonary infection are asymptomatic. However, 
infection in the CNS is usually more serious and can be life threatening and usually present as meningitis 
or meningoencephalitis. Other less common infections include skin, lung, prostate and eye infections. 
[20, 25].   
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2.1.3 Virulence Factors of Cryptococcus neoformans 
 
 
The key virulence factors of C. neoformans are its polysaccharide capsule that prevents phagocytosis, 
melanin production that protects the organism from environmental stresses and  ability of the organism 
to grow at human body temperature of 37ºC [30-32]. There have been various other virulence factors 
established in C. neoformans such as phospholipase B, urease, and many signalling cascades [33-35].  
 
2.1.3.1 Polysaccharide Capsule 
 
The polysaccharide capsule of C. neoformans is a significant virulence factor and is situated just outside 
of the cell wall of the organism. It has been hypothesized that the size of the capsule plays an important 
role in virulence and that the capability of phagocytes to clear the organism in vitro is related inversely 
to the size of the capsule [36, 37]. There are two major components of the polysaccharide capsule, 
which include glucuronoxylomannan (GXM) and galactoxylomannan (GalXM) [38-41]. GXM is the 
most abundant component and makes up approximately 90% of the capsular mass whilst GalXM 
constitutes approximately seven percent of the total capsule mass [41]. Mannoprotein (MP) is a 
nonpolysaccharide component of the capsule, and has been found to represent transient capsular 
components that are destined for cellular exit. [39, 40, 42, 43].  
With regards to environmental growth of the organism, the role of the capsule is not entirely clear 
however there has been some speculation that the capsule acts as a food source and protects the fungus 
from dehydration [39, 44]. During infection in mammals, the capsule plays a role in resisting 
phagocytosis as well as modulating host immune response [39, 45-49]. A possible explanation for 
resisting phagocytosis is that macrophage receptors that bind most of the antigen determinants are at 
the cell wall, and the capsule is able to hide them from phagocytic cells [50]. The capsule also functions 
to protect the fungus after its ingestion, against free radicals, and protects the cell from oxidative bursts 
[39, 51]. There are various studies that show that the capsular components are secreted and this affects 
the host immune response in different ways [52, 53]. Much of the data has focused on the capsular 
component GXM because it is the most abundant. GXM inhibits neutrophil migration in various ways. 
It  prevents leucocytes exiting the blood vessels because of its chemoattracting properties [50, 54]. It 
also induces shedding of L-selectin and E-cadherin from neutrophils and binds to CD18 thus inhibiting 
the binding of leucocytes to endothelium [50, 55-58].  
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The capsule has been shown to produce immunological tolerance in some early studies and this is 
manifested by an inhibition of antibody production against the capsule components [50, 59, 60]. Further 
studies of the capsule showed that both GXM and GalXM interfere with production of cytokines and 
affect dendritic cell maturation and antigen presentation [61-65]. In addition, these components are able 
to induce apoptosis of leucocytes [66-69].  
 
2.1.3.2 Melanin Production 
 
The accumulation of melanin is protective to C. neoformans in that it confers resistance to heat and 
cold, to free radicals and to ionizing radiation [70-72]. Melanin synthesis is dependent on the enzyme 
diphenol oxidase, which is encoded by the genes, LAC1 and LAC2 [50, 73]. In C. neoformans, 
production of melanin  only occurs when exogenous dihydrophenolic compounds are present, since an 
endogenous substrate for this organism is not yet known [39].  
This pigment displays other important characteristics in that it also binds and decreases the 
susceptibility to antifungal agents [50, 74, 75]. Melanin seems  to be an important factor in the 
dissemination of disease from lung to brain [76]. It changes host cytokine production and protects 
against macrophages [50, 77, 78].  
 
2.1.3.3 Survival at Human Body Temperature 
 
Usually, environmental fungi do not tolerate higher temperatures and this includes human body 
temperature [50, 79]. However, most pathogenic fungi appear to have the ability to replicate at 37ºC. 
This seems to be an important factor for it becoming a pathogen in the immunocompromised patient 
[80]. Various processes are involved in enabling replication at higher temperatures. These include 
antioxidant responses, accumulation of trehalose, and stimulation of certain signalling pathways [50, 
81-84].  
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2.1.3.4 Extracellular Enzymes 
 
C. neoformans, like many other fungi, secrete various degradative enzymes such as proteases, DNases 
and lipases. During the course of infection, these  enzymes enhance tissue destruction promoting 
survival of the fungus, and interfere with a competent immune response [39].  
Urease is considered an important cryptococcal virulence factor [33]. This enzyme contributes to the 
organism crossing the blood-brain barrier after its escape from the lung, but once inside the brain, it 
appears not to be required for fungal growth [39, 85]. C. neoformans produces extracellular DNase, 
which degrades host DNA that neutrophils secrete as part of the innate immune response. It could also 
supply the organism with nucleotides [39, 86]. Two superoxide dismutases (SODs) have been reported 
in C. neoformans, which promotes growth of the organism within macrophages [39, 87]. Interestingly, 
temperature influences the production of SOD, where expression is increased at 37ºC, and this may also 
protect the organism against oxidising agents that effector cells of the host produce [39, 88]. The activity 
of phospholipase supports attachment of the fungal pathogen to host cells and various phospholipases 
have been identified in C. neoformans extracellular supernatants [39, 89, 90]. Phospholipase B has been 
shown to promote invasion of host tissue by the fungus and is responsible for hydrolysing phospholipids 
in plasma membrane as well as in lung surfactant [91-93]. It also maintains  integrity of the cell wall 
and provides essential nutrients required by the organism during infection [39]. Another important 
enzyme that contributes to virulence is protease. This enzyme contributes to colonisation, tissue 
invasion and alters host defence response [39].  
 
 
2.2 Cryptococcal meningitis 
 
 
C. neoformans has the ability to cause infection anywhere in the human body. The lung and CNS 
however, appear to have a greater predisposition to infection. The lung usually forms the avenue of 
entry and the symptoms of disease may vary from asymptomatic to severe infection. The most frequent 
manifestation of cryptococcosis is meningitis [94]. Patients present clinically with a variety of 
symptoms and signs. These include headache, fever, cranial neuropathies, altered mental state, malaise 
and loss of memory [25]. Headache appears to be the predominant symptom and is a common finding 
in various studies [29, 95, 96]. Other symptoms are variable and are dependent on the immune status of 
the patient. Clinical signs are usually absent, but when present, include meningism, cranial nerve 
palsies, papilloedema, certain focal neurological deficits and a decreased level of consciousness [94]. 
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Disease severity varies mostly in accordance with degree of immunosuppression and may be acute (a 
few days to a week), sub-acute (2-4 weeks duration) or chronic (extending beyond 4 weeks) [29]. 
Disease of the CNS is life threatening and is a major cause of mortality in patients with HIV especially 
in sub-Saharan Africa with an incidence of 15 to 30% [97]. Of these patients 30 to 60% succumb to 
their illness within 12 months  [20, 97]. In severely immunocompromised patients, there is often a high 
fungal burden in the CSF and these patients tend to have a more acute clinical presentation,  a higher 
CSF polysaccharide antigen titre and weak CSF inflammatory response determined by low white blood 
cell count [25, 94].  
 
 
2.3 Interactions of Cryptococcus with the host immune system   
 
 
 
 
The significant and profoundly more severe course of infection that occurs in the immunocompromised 
population highlights the significance of an effective immune response to this organism. The innate as 
well as the adaptive immune responses have an essential role in host defence against cryptococcal 
infection.  
 
 
2.3.1 Innate Immune Response to Cryptococci 
 
 
Various physical barriers are involved in the initial defence against Cryptococcus. Some of these 
include the skin, nasal mucosa, saliva as well as anti-cryptococcal activity of human serum [98, 99]. 
However, together with these, the main components of the host’s innate immune response to 
Cryptococcus involve the complement system and the phagocytic effector cells.      
 
2.3.1.1 Complement response 
 
The complement pathway consists of a cascade of serum proteins and plays an important role in 
mediating phagocytosis of C. neoformans by the cells of the innate immune system. Studies have shown 
that opsonisation by complement improves the ingestion and inevitably, the death of C. neoformans by 
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phagocytes and mediates dendritic cell responses to the organism [100-103]. Complement activation 
can take place through the classical, lectin or alternative pathway. All of these pathways converge 
eventually to form  C3-convertase and cleaves C3 into C3a and C3b [20]. C3b can either facilitate 
opsonisation and consequently enhance ingestion of the pathogen by phagocytes or it may facilitate 
cleavage of C5 into C5a and C5b [20]. C5a and C3a both act as mediators of the inflammatory response 
and thus attract phagocytic effector cells, while C5b plays a role in initiating membrane attack complex 
(C5b, C6, C7, C8, C9) formation [20, 104]. During cryptococcal infection, two important functions of 
the complement system include stimulation of phagocytic effector cell chemotaxis, and secondly, 
enhancing  Cryptococcus cell ingestion by phagocytes [20]. As previously discussed, the polysaccharide 
capsule of C. neoformans is a well-known and important virulence factor especially important in 
inhibiting phagocytosis. The capsule of C. neoformans inhibits  complement system activation through 
the lectin pathway by inhibiting the binding of mannan-binding lectin [20, 105]. Complement 
component 3 (C3) has been shown to bind to the cryptococcal capsule and is then converted into 
inactivated C3b (iC3b) [100, 106-108]. This enables phagocytosis to occur via complement receptors 
(CR). In vitro studies showed that when these complement receptors (CR1, CR3, CR4) are blocked, 
there is decreased interaction between human macrophages and C. neoformans [102]. While 
complement-mediated phagocytosis has been facilitated by CR3 in murine macrophages, both CR3 and 
CR4 have the ability to mediate complement-independent phagocytosis [100, 109, 110].  
The complement system, being the first line of defence in the bloodstream, is significant in preparing 
for subsequent host responses. The Cryptococcus capsule likely inhibits complement related host 
responses like phagocytosis by suppressing the classical complement pathway and inhibiting C3-
convertase activity by effectively removing C3b which is an important part of the C3-convertase of the 
alternative pathway [20].  
 
2.3.1.2 Phagocytic effector cells 
 
Various phagocytic cells are involved in phagocytosis of Cryptococcus (Figure 2.2). Phagocytosis 
occurs either by directly recognising the organism or through receptor mediated recognition, which 
involves complement or antibodies. Presence of the organism is recognised by cells of the innate 
immune system using pattern recognition receptors (PRR) which are present on host cells. These PRRs 
recognise certain conserved molecular structures called pathogen-associated molecular patterns 
(PAMPs) which can only be produced by pathogens and not host cells. Toll-like receptors (TLRs), non-
TLRs, like intracellular nucleotide-binding oligomerization domain (NOD)-like proteins and the C-type 
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lectin receptors (CLRs) are some of the important PRRs [111-114]. The interaction between PRRs and 
PAMPs allows for activation of innate immune cells and eventually production and release of mediators 
that destroy pathogens and control the adaptive immune response [111].  
i. Dendritic cells 
Dendritic cells (DC) function predominantly in antigen processing and presentation to T-cells and 
to activate adaptive immunity [100, 115, 116]. They are considered major initiators of protective 
cell-mediated immunity during cryptococcal infection [20, 117, 118]. These cells are  important in 
connecting the innate and the adaptive immune response [119]. During cryptococcal infection, DCs 
are responsible for presentation of the major antigens, glycoantigens and mannoproteins which are 
required for activation of T-cell responses [120, 121]. Apart from antigen presentation to naïve T-
cells, DCs regulate the adaptive immune response by producing cytokines [122, 123]. Dendritic 
cells are able to generate differential helper T-cell responses which depend on the type of co-
stimulatory molecules that are expressed on them [122]. There are three main groups of helper  T-
lymphocytes that play a role in fungal infections: (a) helper T-cell type 1 (Th1) , (b) helper T-cell 
type 2 (Th2) and (c) helper T-cell type 17 (Th17) [122]. During cryptococcal infection, a Th1 type 
response is a protective pro-inflammatory response that kills intracellular pathogens whilst a Th2 
response is non-protective and promotes an anti-inflammatory immune response [124-126]. Th17 
cells are often seen in relation with autoimmune diseases and mucosal immunity and during fungal 
infections have protective as well as non-protective roles [127-131]. Therefore, in the division of 
Th-mediated adaptive immune responses, it is important to know the type of antigen-presenting 
DCs [122]. 
 
ii. Macrophages 
Macrophages are phagocytic cells that have for decades been considered the first cell of the innate 
immune system in the host defence against C. neoformans [100]. There are two types of 
macrophages that occur, which include macrophages that remain fixed in tissues, and migrating 
macrophages which are found mainly in interstitial fluid. Macrophages play an important role in 
determining disease outcome by either assisting in clearance of the organism or by aiding in its 
dissemination depending on their activation status [119]. Some researchers have revealed C. 
neoformans to be an intracellular parasite where the organism has found a method to manipulate 
host macrophages [20, 132]. The fungus survives phagocytosis and proliferates within infected host 
cells, which subsequently leads to lysis of the cell, and this is an important route for escape of 
intracellular pathogens [133-135]. Researchers recently have described a non-lytic expulsion 
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mechanism for the organism to be removed from macrophages without destroying the host cell; a 
process which depends on living cryptococci and which occurs very rapidly (< 60 seconds) [20, 
136, 137]. In addition, cryptococci can be transferred from one macrophage to another laterally and 
this does not depend on the route of ingestion or strain of Cryptococcus, but this does depend on 
viability of the cryptococci [20, 133]. A well-known observation is that C. neoformans is able to 
disseminate to different sites in the human body but shows a predilection for the CNS. It seems that 
the intracellular environment within the macrophage is favourable for the organism in that it 
protects it from the immune system thus allowing it to proliferate. A “Trojan horse” mechanism of 
dissemination has been described by some authors, which implies that the replication intracellularly 
within macrophages, the transfer laterally between them and their exit from macrophages could 
explain how the organism remains latent and therefore disseminates in the host without activating 
immediate immune responses [20, 138, 139]. In fact, it is thought that lateral transfer and expulsion 
particularly, might be responsible for the yeast being able to cross the blood-brain barrier by 
possibly being transferred by macrophages directly to its endothelial layer and then being released 
into the CNS [20]. Two phenotypes appear to be important determinants of whether macrophages 
are beneficial or harmful during cryptococcosis: the classically activated macrophages (M1) or 
alternatively activated macrophages (M2) [119]. M1 macrophages are involved in eradicating 
Cryptococcus by their ability to produce reactive oxygen species (ROS) and reactive nitrogen 
species (RNS) while M2 macrophages allows persistence of infection by supporting intracellular 
survival and proliferation of cryptococci [119, 140]. The ability to polarize towards either M1 or 
M2 macrophages depends on the cytokine response during infection [141].  In pulmonary 
cryptococcal infection for example, the cytokine profile needed to activate M1 macrophages 
depends on a cytokine environment that is IFN-dominant, whereas for M2 macrophages activation 
requires a cytokine profile that is IL-4 or IL-3-dominant [119, 142, 143]. 
 
iii. Neutrophils 
Neutrophils are phagocytic cells that migrate to the site of infection, release enzymes against 
microbes and produce neutrophil extracellular traps (NETs) [100, 144]. They are considered the 
“rapid responders” of innate immunity and are considered the most important immune cells that 
control the early stages of many fungal infections [145]. These cells are also the most abundant 
leucocyte type in human blood accounting for 40 – 75% of all leucocytes [145]. Neutrophils are 
derived from bone marrow precursors, are very motile and importantly, have a relatively short life-
span [145].  Although neutrophils have been shown to have clear roles in the innate response to 
other fungi such as Aspergillus fumigatus, their role in defence against Cryptococcus species is not 
clear [100, 146]. Previous in vitro studies have shown human polymorphonuclear leucocytes 
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(PMNs) to have activity against cryptococci by oxidative and non-oxidative mechanisms like 
hydrogen peroxide, hypochlorous acid, calprotectin, and defensins [147, 148]. Complement, 
especially C5b acts as a chemoattractant thus causing neutrophils to migrate towards the C5b coated 
Cryptococcus [148, 149]. However, despite neutrophils ability to kill this organism, C. neoformans 
capsular component GXM has been shown to inhibit migration of neutrophils, neutrophil 
extracellular trap (NET) formation, killing and respiratory burst [3, 150-152]. Therefore in view of 
data that show only low numbers of neutrophils present in infected tissues during early infection it 
might suggest an immune-regulatory rather than an antimicrobial role for neutrophils [20, 135].  
Complement receptor 3 (C3) and Fc-γ R are significant human neutrophil receptors which recognise 
C3b and IgG opsonised fungal pathogens (Figure 2.1) [145]. Fungal contact with these receptors 
initiates signalling cascades, which stimulates various mechanisms such as phagocytosis, oxidative 
burst, NET, and release of antimicrobial peptides from neutrophil granules [145]. All of these 
contribute to fungal killing. Neutrophils also secrete cytokines and chemokines during fungal 
contact which leads to recruitment of further immune cells [145].  
 
Figure 2.1 Neutrophil function in antifungal immune response 
 
Hunniger K, et al, 2019, 89, 3-15 
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iv. Natural killer cells 
Natural killer (NK) cells are cytotoxic cells that form part of the innate immune system. Some 
studies have shown that these cells play a role in defence against cryptococci in murine experiments 
through direct cytotoxic effect against the organism [100, 153-155]. Other studies in mice suggest 
that NK cells enhance the ability of macrophages to kill fungal cells by producing interferon gamma 
(IFNγ) [156, 157]. In human studies, NK cells and T-lymphocytes inhibit growth of Cryptococcus 
through direct interaction with the organism [158, 159]. NK cells express granulysin and perforin 
but perforin only is required for anti-cryptococcal activity by NK cells [148, 160]. 
 
v. Eosinophils 
Eosinophils are granulocytes that are especially known for their role in allergies and parasitic 
infections [100]. In rats, it was established that C. neoformans  was phagocytosed by eosinophils 
and that eosinophils  primed B and T cells to generate protective host Th1 responses [100, 161-
163].  There is however, no clarity on whether eosinophils have any significant role in innate 
immunity to C. neoformans or whether their recruitment is just a by-product of an inadequate Th2 
response [100].    
 
 
2.3.1.3 Pattern Recognition Receptors 
 
Usually, pathogens are recognised by PRRs on host cells, which recognise PAMPs that are produced 
by the pathogen. This interaction of PRRs and PAMPs induces signal transduction, which allows for 
innate immune processes to occur. Components of the cell wall including glucans, mannans and chitin 
are common fungal PAMPs. C. neoformans polysaccharide capsule has the ability to mask these 
PAMPs and interestingly, PRRs such as C-type lectin receptor (CLR) and Toll-like receptor (TLR) 
families, that usually detect other fungi, do not play similar roles in recognising C. neoformans [100]. 
The process involved in the recognition of C. neoformans  by the host therefore, is still not clearly 
defined [100].  
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i. Toll-Like Receptors 
Of the PRRs , TLRs are the family studied most extensively, with 13 known members coded for in 
the human genome [119]. These receptors are able to recognise bacteria, viruses and fungal 
pathogens and they play a role in regulating both the pro-inflammatory as well as the anti-
inflammatory immune responses. Most TLRs recognise PAMPs and this initiates signal 
transduction cascades that are associated with the adaptor molecule myeloid differentiation primary 
response protein 88 (MyD88) [119]. Evidence that MyD88 is involved in anti-cryptococcal 
responses in rats supports the possible involvement of TLRs as cryptococcal PRRs [164, 165]. 
However, there is still insufficient experimental evidence that supports the role of many of the TLRs 
in cryptococcal infection [100]. 
TLR2 and TLR4 are able to recognise several pathogen ligands especially cell wall-associated 
ligands and this has earned them much attention among researchers [119]. TLR2 and TLR4 are cell 
surface receptors and are expressed on many innate cells such as neutrophils, macrophages, 
monocytes,  and DCs [166]. β-glucans that are expressed in the fungal cell wall are usually 
recognised by TLR2, however the capsule of C. neoformans has the ability to conceal the β-glucan 
layer [167]. The function  of TLR2 during the immune responses to cryptococci appears to be varied 
among studies [119].  
Microglial cells, which are the resident phagocytes within the CNS, as well as meningeal 
macrophages, make up the first line of defence within the brain during infections of the CNS [168-
170]. These cells may be found throughout the brain parenchyma and constitutes between 10 and 
20% of the glial cell population in the CNS [171]. Koutsouras et al found that a comparison between 
microglia and macrophages aided in the understanding of microglial physiology. However, unlike 
macrophages, microglial cells maintain themselves entirely by self-replication [171]. Perivascular 
microglial cells, also named perivascular macrophages, are derived from bone marrow and are 
maintained continuously from the periphery while simultaneously being maintained by the self-
replication properties of parenchymal microglia [171, 172]. During infection, these cells release 
chemokines which increase recruitment of dendritic cells, neutrophils, and lymphocytes from 
peripheral tissue [171]. Microglial cells express TLRs, which identify PAMPs and are therefore 
important in regulating the innate immune response [170, 173, 174]. TLR2 as well as TLR4 are 
known to recognize cryptococcal GXM [170, 175]. It was determined that GXM had the ability to 
bind to TLR2 and TLR4 with the co-receptor CD14 but it was unable to activate the MAPK 
(mitogen-activated protein kinase) pathway and produce TNF-α [170, 175]. TLRs also have the 
ability to form heterodimers like TLR1/2 and TLR2/6 that recognize GXM in the cryptococcal 
capsule [176]. In vitro studies show that  O-linked mannans activate TLR4 in C. neoformans [119]. 
Furthermore, pro-inflammatory responses were increased in C. neoformans infection when 
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microglial cells were stimulated with TLR1/2, TLR3, TLR4, and TLR9 (TLR agonists), however, 
the significance is not clear [170].  
While TLR function in the lymphatic system has stimulated much interest in recent years, not much 
information is available on the expression and role of TLRs in CNS microglial cells [7]. It is 
however, well established that these cells do participate in the innate immune response [177]. 
Emerging data is becoming available on TLR expression in the rodent CNS, however minimum 
information is available on expression of TLRs in human microglial cells [7]. 
 
ii. C-type Lectin Receptors 
The C-type Lectin Receptors (CLRs) are a group of receptors that recognise fungal carbohydrate 
ligands such as β-glucans and mannans [100]. CLRs usually initiate signalling pathways through 
their own intracellular signalling domain or via signalling adapters that have an immunoreceptor 
tyrosine-based motif (ITAM) [100]. It has been established that CLRs play a role in host immune 
responses to other fungi, however their role in C. neoformans is not significant [100, 178]. Evidence 
exists that β-glucans are accessible on capsules of  C. neoformans, however, in vivo, it seems 
evident that the capsule interferes with many of these interactions [179, 180].  
 
iii. Nucleotide-Binding Oligomerization Domain (NOD)-Like Receptors 
NOD-like receptors (NLRs) are cytoplasmic PRRs that share a role in immunity and are able to 
recognise PAMPs and damage-associated molecular patterns (DAMPs) [119]. Some studies 
recently, have shown that NLRs were involved in sensing the presence of fungi [119]. C. 
neoformans cells stimulated formation of the NLRP3 inflammasome, and studies with mice that are 
deficient in the NLRP3 inflammasome components showed that they were more susceptible to 
infection [181-183]. However, sufficient information on the role of NLRs in response to C. 
neoformans is not available [100].  
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2.3.2 Adaptive Immune Response  
 
2.3.2.1 Cell-mediated Immunity: T-cells  
 
The patient group predominantly at risk for developing cryptococcal disease usually have severe T-cell 
function defects [148]. This clearly indicates that T-cell mediated immunity plays a vital role in the 
control of cryptococcal infections (Figure 2.2). Both CD4 and CD8 cells inhibit C. neoformans, either 
directly or by producing pro-inflammatory cytokines that are required for recruiting and activating other 
phagocytic cells to kill the organism [122, 184-186]. A review of in vitro studies indicate that CD4 and 
CD8 T cells both produce Th1 cytokines, however the sole source of Th2 cytokines are the CD4 T cells 
[122]. Various T cell subsets exist that have a function in cryptococcal infection. Regulatory T-cells are 
protective against cryptococcal infection in that they suppress the damaging Th2 immune response 
[122]. Other examples of T-cell subsets include NK cells, Natural killer T (NKT) cells and gamma delta 
T (γδT) cells which all play a role in in protective immunity against cryptococcal infection [122, 187, 
188]. T-cells however, are also able to downregulate the protective Th1 response [189]. 
The proliferation of naïve T-cells may be induced by complete cryptococcal cells or by cell extracts 
such as cell wall and cell membrane protein extracts [190, 191]. To ensure presentation of C. 
neoformans antigen to T-lymphocytes, it is necessary for phagocytosis and protein processing to occur 
[192]. Cryptococcal cells are then either inhibited or killed by CD4 and CD8 T cells.  
 
2.3.2.2 Antibody-Mediated Immunity 
 
There has been conflict regarding the role of antibody-mediated immunity in cryptococcal infections. 
There are however, many reports of cryptococcal infections in patients who have B-cell deficiencies, 
as well as antibody or even lymphoproliferative deficiencies [193]. In addition, antibodies against 
cryptococcal proteins and capsular components have been found in people without infection [20, 194, 
195]. In HIV-patients, there is an association with cryptococcal infections when there is a decrease in 
B-cells secreting IgM [196]. Anti-cryptococcal antibodies opsonise the pathogen resulting in Fc 
receptor-dependant phagocytosis and activation of the classical complement pathway [20]. Studies in 
mice indicate that the protective effect of antibodies may be to an extent, due to interactions with cell-
mediated immunity [20]. Some studies show that antibody responses may amplify cryptococcal disease 
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in humans [122]. In non-HIV patients with normal CD4 counts autoantibodies have been associated 
with infection [197].  
 
2.3.2.3 Cytokine response 
 
Knowledge regarding cytokine response has been obtained predominantly in mouse models and 
therefore information and evidence regarding their response in cryptococcal infection relates to mouse 
models [198-200]. Cytokines consist of proteins, peptides or glycoproteins that are secreted by immune 
cells and have a role in mediating and regulating immunity. Various cytokines and chemokines are 
involved in cryptococcal infection. These cytokines and chemokines either induce the Th1 response 
and/or suppress Th2 immune responses [122]. Both protective and non-protective cytokines are 
produced during infections by C. neoformans. Protective cytokines include IFN-γ, IL-12 and IL-2 which 
have been shown in humans as well as mouse models [122]. Additionally, other protective cytokines 
have been identified which include TNF-α, IL-6, IL-8, IL-18, IL-23, and IP-10 [122]. Non-protective 
cytokines include IL-5 and IL-13, which are the Th2 cytokines, and these cytokines stimulate 
cryptococcal disease. There are certain cytokines/chemokines that may play a dual role in protection as 
well as disease aggravation during cryptococcal infection, and these include IL-4, IL-8, IL-10, IL-1β, 
MCP-1 (monocyte chemoattractant protein 1), MIP-1α (macrophage inflammatory protein form 1 
alpha) and RANTES (CCL5) [122].  
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Figure 2.2 Innate vs Adaptive Immunity 
 
Nature Reviews Cancer, 4, 11-22 
 
2.4 Paucity of neutrophils in cryptococcal meningitis 
 
 
 
 
Cryptococcal meningitis is known to be characterized by a relative paucity of leucocytes in the CSF 
compared to that in bacterial meningitis. [3-5, 56, 201]. The presence of leucocytes is regulated through 
chemotaxis. Chemotaxis is dependent on chemokine production at the infection site and the level of 
expression of corresponding chemokine receptors on the migrating cells. Chemokines are important in 
mediating recruitment of leucocytes into infection sites, including infections with C. neoformans [202]. 
Microglial cells in the brain are important sources of IL-8, IP-10, MIP-1, MIP-1, RANTES, KC, and 
MCP-1[203]. Chemokines are produced when TLRs on cells at the site of infection recognize specific 
microbes. For C. neoformans, TLR2 has been identified as a significant TLR [6, 7, 175].  
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TLR2 and TLR4, as described above, are receptors found on the cell surface that enable phagocytic 
inflammatory responses to various microbial products. When these receptors are activated, signaling 
cascades are triggered and this results in a pro-inflammatory response including production of TNF. 
[175]. Whilst it is clear that TLR expression is significant, there is not much published information on 
expression and function of TLRs in human CNS microglial cells [7]. 
 
High levels of the capsular components GXM, GalXM, MP-1, and MP-2 is characteristic of 
disseminated cryptococcal infection, in the CSF and serum of patients [3]. These components induce 
peripheral blood monocytes and polymorphonuclear neutrophils (PMN) to produce the cytokines TNF-
 and IL-1 [3]. TNF- and IL-1 stimulates endothelial cells, astrocytes and mononuclear cells to 
produce IL-8 in the brain of patients with meningitis.[3]. IL-8 is a potent chemo-attractant for PMNs 
[3]. However, in cryptococcal meningitis, there is a paucity of PMNs [4, 5, 56, 201].  
 
A study by Lipovsky et al [5] confirmed what others have observed that GXM has chemoattractant 
activity. They have suggested that IL-8 production occurs in the brain but neutrophils do not cross the 
blood brain barrier (BBB) in response to IL-8. Their explanation is that migration of PMNLs does not 
occur because a chemotactic gradient does not exist across the blood brain barrier. Furthermore, a 
phenomenon called cross-desensitization of the IL-8 receptor could be another possible explanation for 
chemotaxis inhibition by GXM [5, 204]. 
 
Glucuronoxylomannan has been observed to inhibit adhesion of PMNs to activated endothelium in a 
concentration-dependent manner [56]. Furthermore, another component of the capsule, MP-4, was 
studied as a new capsular antigen which activates neutrophils and desensitizes them toward a 
chemotactic challenge [3]. 
Another possibility for the paucity of leucocytes is that even though IL-8 was produced in the CSF of 
patients with cryptococcal meningitis, the circulating GXM was downregulating recruitment of 
leucocytes, perhaps through shedding of L-selectin, thus impairing migration of leucocytes into the CSF 
[205, 206]. 
 
A series of steps are involved during the inflammatory response with regards to leucocytes and 
endothelium interactions [57]. These progress from rolling to adhesion and ultimately migration into 
tissues. Margination and rolling of leucocytes on the cytokine-activated endothelium are the first steps 
in adhesion [57, 207]. It was shown that GXM impedes the early rolling phase of neutrophil adhesion 
to endothelium and to Chinese Hamster Ovary (CHO) cells that were E-selectin-transfected [57]. 
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Various observations as described above suggest the presence of neutrophil chemokines in the brain of 
infected patients and that microglial cells are a potent source, yet a paucity of neutrophils still occurs in 
cryptococcal infection. Toll-like receptors have been described as receptors involved in initiating 
phagocytic inflammatory responses, however little evidence is available on its expression and function 
in human microglial cells. This study therefore aims to describe this. 
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CHAPTER 3 – METHODS 
 
3.1 Patient Recruitment and Clinical Data 
 
 
A prospective study was conducted at a regional hospital in KwaZulu-Natal, South Africa, from 16 July 
2013 to 03 February 2016. HIV infected adult patients with a diagnosis of meningitis with Cryptococcus 
neoformans as causative agent were invited to participate in the study. The criteria for exclusion were 
age <18 years, HIV uninfected, and concomitant infections other than HIV. The diagnosis was made 
on clinical grounds and confirmed by laboratory examination of CSF. Only patients with isolates 
identified as C. neoformans were included (3.3). Patients who provided written informed consent were 
enrolled in the study within 24 hours of presentation. Clinical details were recorded and a second lumbar 
puncture was performed 48 hours following presentation as part of the routine patient work-up and CSF 
opening pressure was recorded. Two tubes with CSF as well as two with venous blood collected at this 
time point were transported to the laboratory. A total of 71 patients who fulfilled all the criteria were 
enrolled in the study. None of the patients had received prior antifungal treatment. Antifungal therapy 
was commenced after the first CSF specimen was collected. 
 
3.2 Quantification of Immune Cells in CSF and Blood 
 
3.2.1 Quantification of Immune Cells in CSF 
 
 
Cells in the CSF were quantified using a haemocytometer (Thermo Fischer Scientific, Massachusetts, 
USA). One drop of trypan blue was added to a clean tube using a sterile glass pipette. Nine drops of 
CSF was then added to the same tube using an equivalent glass pipette. This made a 1:10 dilution. This 
was left to stand for five minutes to allow the cells to absorb the stain. The solution was mixed by gently 
tapping the bottom of the tube. A coverslip was placed over the counting chamber and using a capillary 
tube the counting chamber was filled with the diluted specimen. It must be noted that the counting 
chamber can only accommodate a predetermined fixed volume of 20 μl. The slide was then viewed 
under a light microscope using a 10× objective and the number of cells were counted using a cell 
counter. A standard formula was used to calculate number of cells (Appendix A1). 
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3.2.2 Quantification of Immune Cells in Blood 
 
 
A full blood count was performed using an automated system (Advia 2120i, Siemens, Munich, 
Germany). A differential count was performed using the same instrument. Enumeration of neutrophils 
was done by establishing the percentage of these cells from the total white blood cell count using the 
same automated instrument. 
 
3.3 Microscopy and Culture of CSF Specimens 
 
 
The first CSF received from the patient was centrifuged at 1109 × g for 10 minutes. The supernatant 
was aseptically decanted into a sterile capped tube labelled with the study number. The deposit was 
resuspended in the remaining supernatant by gently tapping the bottom of the tube. A smear was 
prepared by placing one drop of the resuspended deposit onto a sterile glass slide using a sterile pipette. 
The slide was allowed to air dry followed by Gram staining (Appendix A2). Fifty microliters of the 
deposit were inoculated onto sheep blood agar (Appendix B1), and incubated at 37°C for 48 hours in a 
regular incubator. Each isolate was identified to species level using the automated Vitek® 2 system 
(bioMérieux, France).  The CSF supernatant was used to perform a Cryptococcus latex agglutination 
test (3.4).  
 
3.4 Concentration of Capsule Material Components in CSF and Serum 
 
3.4.1 Principle of the Cryptococcal Antigen Latex Agglutination Test 
 
 
The Cryptococcal Antigen Latex Agglutination System (CALAS® - Cryptococcal Antigen Latex 
Agglutination System, Meridian Bioscience Inc., Ohio, USA) was used to measure the titre of 
cryptococcal antigen in serum and in CSF. This was used as a proxy for the amount of shed capsular 
material. The procedural instructions by the manufacturer were followed to complete the tests. CALAS 
utilizes latex particles coated with rabbit anti-cryptococcal IgG in glycine buffered saline (pH 8.4 ± 0.1) 
that contains a preservative thimerosal (< 0.01%). This is referred to as detection latex. Visible 
agglutination is observed when the antibodies on the latex particles and the cryptococcal polysaccharide 
antigen bind together. Latex particles that were coated with immune-globulins not containing 
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cryptococcal binding sites were used as negative control. The positive control consisted of purified C. 
neoformans polysaccharide antigen, which contained the preservative thimerosal (0.01%). Goat anti-
rabbit serum with thimerosal (0.01%) was the antibody control. Macroglobulins such as rheumatoid 
factor may be present that could cause nonspecific agglutination. If this does occur specimens are 
treated with pronase (Appendix B2) to remove these macroglobulins.  
 
3.4.2 Procedure of the Cryptococcal Antigen Latex Agglutination Test 
 
 
One free falling drop of positive control was added to the two designated rings on the reaction card 
provided with the kit. Twenty-five microliters each of the antibody and negative controls were pipetted 
to the relevant rings. Twenty-five microliters of patient CSF supernatant was pipetted into each of the 
two rings on the test-card. Thereafter, one free falling drop of the detection latex was added into each 
ring. Similarly, one drop of negative control latex (3.4.1) was added into the additional rings. The 
contents of the different rings were then mixed using separate applicator sticks. Subsequently, the card 
was placed on a horizontal rotator and rotated at 0.4 × g for 5 minutes. Results were read immediately. 
 
3.4.2.1 Titrations 
 
 
Two-fold serial dilutions of each specimen were done until the agglutination end point was reached.  
Two hundred and fifty microliters of sample diluent (Appendix B3) was added into five labelled test 
tubes and placed in a rack. Using a clean pipette, 250 l of CSF or serum was added into tube labelled 
1 and mixed well. Two hundred and fifty microliters from tube 1 was then transferred to tube 2 and 
mixed well. Following this pattern, the dilution series was continued through to tube five. Two hundred 
and fifty microliters from tube 5 was transferred into a “holding” tube to allow for further dilutions that 
may be necessary. Thereafter, the same antigen detection procedure as described in 3.4.2 was followed.  
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3.5 Storage of CSF and Blood specimens 
 
 
The second tube with CSF from each patient was centrifuged at 1109 × g for five minutes. The 
supernatant was aseptically decanted into at least two sterile cryovials labelled with the study number 
and stored at -80°C. The deposit was resuspended by gently tapping the bottom of the tube and 
inoculated onto sheep blood agar (Appendix B1). After 48 hours of incubation at 37°C, the growth was 
harvested using a sterile plastic loop and suspended in 1 mL of sterile distilled water. These suspensions 
were stored at room temperature for further work (Appendix A3). 
Blood specimens were centrifuged at 1109 × g for 5 minutes. The serum was then aseptically decanted 
into at least two sterile cryovials with labelled with the study number and stored at -20°C. 
 
3.6 Retrieval of Stored Cryptococcus Cultures for Determination of Capsule Thickness 
 
 
Stored Cryptococcus suspensions were plated out on Brain Heart Infusion Agar plates (Oxoid Ltd, 
Cheshire, England) supplemented with 10% Horse blood (Appendix B4). These were incubated for 48 
hours at 37°C aerobically.  
 
3.6.1 Determination of capsule thickness 
 
 
A microscopy slide was made on the first subculture of organisms grown from the 48-hour specimen 
obtained by lumbar puncture (3.6). Anthony’s capsule stain was applied to visualize the polysaccharide 
capsule [208].  
 
3.6.1.1 Principle of Anthony’s Stain 
 
  
This procedure for staining capsules contains crystal violet as the primary stain, which is taken up by 
all parts of the cell. A 20% copper sulphate solution is used as a decolorizing agent as well as a counter 
stain. When the copper sulphate washes out the crystal violet, the capsule becomes decolorized but not 
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the cell. As the copper sulphate decolorizes the capsule, it simultaneously counter stains the capsule. 
The capsule therefore can be visualised as a faint blue halo surrounding a purple cell. 
 
3.6.1.2 Preparation of the inoculum 
 
i. Determining Yeast cell concentration of 1-McFarland Standard for Cryptococcus 
 
 
A suspension of the culture was made in phosphate buffered saline, pH = 7.2 (Appendix B6) and 
adjusted to a 1-McFarland suspension (Appendix B5) which is equivalent to a suspension of 3.0 × 10⁸ 
CFU/mL for bacteria of average size (0.5 – 2.0 μm). Considering that C. neoformans is larger than an 
average bacterial cell (5 – 10 μm vs 0.5 – 2.0 μm), the concentration of the yeast cell equivalent to a 1-
McFarland standard was determined. A series of 1:10 dilutions was made in RPMI with L-Glutamine 
(Lonza Group Ltd, Basel, Switzerland) starting with a density of 3.0 × 10⁸ CFU/mL and ending at 1.0 
× 10² CFU/mL. Ten microliters of each suspension was inoculated on individual sheep blood agar plates 
and incubated aerobically for 48 hours at 37°C. This was performed in duplicate. Thereafter, colonies 
were counted on the plates that contained on viewing 20 – 200 colonies.  The average number of 
colonies was then adjusted for volume and inoculum size and thus it was determined that the bacterial 
1-McFarland standard was equivalent to 1.0 × 10⁶ CFU/mL for C. neoformans. 
 
3.6.1.3 Anthony’s staining procedure 
 
 
Fifty microliters of the cryptococcal suspension was placed on a glass slide and a thin film was made 
using a second slide under an approximately 45o angle. After air drying, the slide was flooded with 1% 
crystal violet for two minutes [208]. It was then rinsed gently with a 20% copper sulphate solution and 
air-dried.  It is not recommended to blot the slide because blotting removes the un-fixed microbes from 
the slide and cause disruption of the capsule [208]. The slide was viewed under an oil immersion lens 
(Leica DM 3000; Leica microsystems, Wetzlar, Germany). Bacterial cells and the proteinaceous 
background appeared purplish while the capsules appeared transparent. Photographs were taken of the 
organisms on the slide and viewed at a magnification of 100×.  A camera (Image Pro-Plus of Media 
Cybernetics, Inc., Maryland, USA), was used to capture these images. The number of images taken 
depended on the density of cryptococcal cells on the slide. The images were used to measure the capsule 
thickness. This was done by first measuring the diameter of the entire cell including the capsule 
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followed by measuring the smaller diameter of the cell excluding the capsule. The difference between 
the two diameters was recorded as the capsule thickness in micrometers. The average capsule size of 
each isolate was determined using three different cryptococcus capsule measurements per isolate. Three 
cells per isolate were randomly selected on three microscopic fields and capsule measurements were 
performed as described above. 
 
3.7 Neutrophil Chemotaxis Inhibition 
 
 
Neutrophil chemotaxis inhibition experiments were performed to compare the number of migrating 
neutrophils toward the chemoattractant (E. coli), with the number of neutrophils that migrate toward 
the chemoattractant mixed with the cryptococcal isolates. The amount of inhibition was determined by 
calculating the difference between these two values (no. of migrated neutrophils towards E. coli – no. 
of migrated neutrophils towards E. coli/Cryptococcus combination = Chemotaxis inhibition). 
A qualitative approach using the Boyden Chamber method was used. A gradient separation method was 
used to separate neutrophils from the rest of the human blood cells (3.7.2.2).  
 
 
3.7.1 Boyden Chamber assay 
 
 
The Boyden Chamber method [209, 210] was used to determine the rate of neutrophil chemotaxis in 
the presence and absence of C. neoformans yeast cells. Escherichia coli ATCC 25922 was used as the 
chemoattractant. This assay is based on a chamber that consists of two compartments that are separated 
by a microporous membrane. The assay was developed originally by Boyden to analyse leucocyte 
chemotaxis  [211]. Cells added into the upper compartment migrate through the membrane pores into 
the lower compartment, which potentially contains the chemotactic agents. The chamber is incubated 
for an appropriate/predetermined time, following which the membrane between the two compartments 
is fixed and stained and the number of migrated cells in the lower compartment is determined using a 
cell counting method. This assay has therefore also been called “filter membrane migration assay”, 
“trans-well migration assay”, or “chemotaxis assay” [211]. Various different Boyden chamber devices 
are available commercially. Here, Transwell® inserts (Corning Life Sciences, New York, USA) in 24-
well tissue culture plates were used. 
 
 
30 
 
3.7.2 Preparation for the Transwell Migration Assay 
 
3.7.2.1 Acquisition of neutrophils from volunteer donors 
 
 
Healthy adult volunteers were recruited with informed consent to donate blood on the day of an 
experiment. Approximately 25 mL of blood was drawn from one donor. Blood samples were collected 
in EDTA tubes (BD Life Sciences, New Jersey, USA) and transported immediately to the laboratory 
for neutrophil separation. 
 
 
3.7.2.2 Neutrophil separation 
 
 
A gradient separation method using Histopaque®-1119 (Sigma-Aldrich, Missouri, USA) and 
Histopaque®-1077 (Sigma-Aldrich, Missouri, USA) was used in the laboratory to separate neutrophils 
from the rest of the human blood cells. The procedure was followed according to specifications by the 
manufacturer. Before commencing on the separation procedure, cells and plasma were mixed evenly 
by gentle tilting of vials. Twelve millilitres Histopaque®-1119 was added to a 50 mL conical centrifuge 
tube using a sterile needle and syringe. Twelve milliliters of Histopaque®-1077 was then carefully 
layered onto the Histopaque®-1119 using a sterile needle and syringe. This was followed by carefully 
layering 24 mL of whole blood onto the upper gradient of the tube using a sterile needle and syringe. 
Without disturbing the gradients, the tube was centrifuged at 700 × g (centrifugal force) for thirty 
minutes at room temperature (25°C). Two distinct opaque layers were visible, one containing 
mononuclear cells and platelets and the other containing granulocytes including the neutrophils. The 
granulocyte layer was gently aspirated using a sterile Pasteur pipette (Sigma-Aldrich, Missouri, USA) 
and cells were transferred to a sterile 15 mL conical centrifuge tube. The cells were washed by adding 
10 mL of isotonic phosphate buffered saline (PBS), pH = 7.2 (Appendix B6). This was centrifuged at 
200 × g for 10 minutes at room temperature (~25°C). The supernatant was removed using a sterile 
Pasteur pipette and discarded. The cells were resuspended by gentle aspiration three times with a sterile 
Pasteur pipette. The wash step was repeated for a further two times. Cells were then resuspended in 
isotonic PBS, pH = 7.2 to achieve a cell count of 1 × 10⁶ cells/mL [212]. To determine the dilution 
factor to obtain this neutrophil concentration, a cell count was done using a haemocytometer as 
described previously (Appendix A1). Further dilutions were made as required. The purity of the 
neutrophil suspension was tested by means of the Giemsa staining method (Appendix A4) 
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3.7.2.3 Preparation of the inoculum of C. neoformans isolates and E. coli ATCC 25922 
 
 
For C. neoformans, in a series of preliminary experiments (3.6.1.2), the appropriate density was 
determined to be 1.0 × 10⁶ CFU/mL and for E. coli, it was determined to be 3.0 × 10⁸ CFU/mL. 
Therefore, a 1-McFarland suspension of each organism suspension was used in the chemotaxis assay.  
For the E. coli/Cryptococcus mixture, equal volumes of the E. coli ATCC 25922 (3.0 × 10⁸ CFU/mL) 
and C. neoformans (1.0 × 10⁶ CFU/mL) suspensions were mixed in a sterile tube at a 1:2 dilution for 
each organism. Thus, a suspension of each culture was made in PBS, pH = 7.2 containing 0.5 × 10⁶ 
CFU/mL Cryptococcus and 1.5 × 10⁸ CFU/mL E. coli. The mixed suspension contained the same 
amount of microbes of each species as above. For the Transwell assay the cryptococcal suspension, the 
E. coli suspension as well as the mixed suspension were used. 
 
 
3.7.3 Transwell Assay 
 
 
Twenty-four well tissue culture plates that have inserts in the plate with a collagen-coated membrane 
of 3-μm pore size were used (Figure 3.1). Transwell® inserts (Corning Life Sciences, New York, USA) 
were used. A  membrane with a 3 μm pore size was used to ensure that neutrophils actively migrate 
through them to the lower chamber (baso-lateral compartment) and move through freely [213].  Six 
hundred microliters of organism suspension was added to the bottom of a well of a 24-well plate. The 
Transwell membrane filter was then placed carefully in the same well. Typically 1.0 × 10⁶ cells/mL is 
used for nearly all types of cells when using the 24-well Transwell insert [212]. One hundred microliters 
of neutrophil cell suspension was added onto the top (upper compartment) of the filter membrane. These 
volumes were determined to ensure that the suspension medium in the bottom of the well makes contact 
with the membrane to form a chemotactic gradient [212]. The assay was incubated at 37°C for 30 
minutes. The number of migrated cells was determined using the Myeloperoxidase (MPO) Human 
SimpleStep ELISA® Kit (Abcam®, Cambridge, UK)). As described in 3.7, the chemotaxis assay was 
performed with each cryptococcal isolate alone and a combination of the same cryptococcus plus the 
chemoattractant (E. coli ATCC 25922). E. coli (ATCC 25922) alone was used as the control. The 
amount of inhibition was determined by calculating the difference between two values ( no. of migrated 
neutrophils towards E. coli – no. of migrated neutrophils towards E. coli/Cryptococcus combination = 
Chemotaxis inhibition). All experiments were performed in duplicate.  
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The following preliminary experiments were performed to determine i. the most appropriate 
chemoattractant (control organism) for the experiment, ii. the most appropriate incubation time to allow 
for chemotaxis, iii. the most appropriate density or concentration of test organism (C. neoformans), and 
iv. the most appropriate means for quantification of migrated neutrophils across the transwell 
membrane. 
 
 
Figure 3.1 Transwell Migration Assay Diagram 
 
 
 
 
 
 
3.7.3.1 Preliminary Experiments  
 
i. Determination of chemoattractant 
 
Four organisms were tested as possible chemoattractants in the Transwell migration inhibition assay as 
described above. These were C. albicans ATCC 14053, E. coli ATCC 25922, H. influenzae ATCC 
49427, and K. pneumoniae BAA 1705. Six 1:10 serial dilutions of a 1-McFarland standard for each 
organism were made using RPMI with L-glutamine (Lonza Group Ltd, Basel, Switzerland) as the 
diluent. The Transwell Migration procedure as described above (3.7.3) was performed for each of the 
four organisms with each of the dilutions. Migrated neutrophils were counted using a haemocytometer 
and enumeration of neutrophils were performed manually according to predetermined calculations 
(Appendix A1). The highest yield of migrated neutrophils was obtained with the highest dilution 
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microbe concentration for three of the four isolates tested. E coli yielded a total count of migrated 
neutrophils of 1.0 × 10⁵ cells/mL, H. Influenzae, 0.2 × 10⁵ cells/mL, and K. pneumonia, 0.2 × 10⁵ 
cells/mL. C. albicans ATCC 14053 was determined to be an inappropriate chemoattractant control to 
be used in this assay, because it was difficult to distinguish between the organism and the migrated 
neutrophils in the haemocytometer. Therefore, it was determined that a McFarland-1 suspension of E. 
coli ATCC 25922 would be used. 
 
  
ii. Determination of incubation time for chemotaxis 
 
E. coli ATCC 25922, H. influenzae ATCC 49427, and K. pneumoniae BAA 1705, at densities of 3.0 × 
10⁸ CFU/mL were used in this experiment. The Transwell Migration procedure as described above 
(3.7.2) was performed for each of the three control organisms for the following incubation periods: 30 
minutes, 60 minutes and 90 minutes. The results obtained are illustrated in Table 3.1. 
 
 
 
TABLE 3.1:  Neutrophil count after 30, 60, and 90 minutes incubation  for control 
                      organisms     
      
    incubation time (minutes)    
  control organism 30 60 90  
no. of neutrophils 
(cells/mL) 
E. coli ATCC 
25922 
1.0 × 10⁵  0.3× 10⁵ 0.0 
 
 H. influenzae 
ATCC 49427 
0.2 × 10⁵  0.2 × 10⁵  0.0 
 
  
K. pneumoniae 
BAA 1705 
0.2 × 10⁵  0.0 0.0 
 
 
 
From this experiment, E. coli ATCC 25922 displayed the highest cell count at an incubation period of 
30 minutes. The other two organisms had lower cell counts than E. coli after 30 minutes of incubation. 
After 60 minutes of incubation, all three organisms yielded lower counts compared to 30 minutes of 
incubation. After 90 minutes, the cell count for all three organisms was zero. Therefore, an incubation 
time of 30 minutes was adopted. 
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iii. Inoculum size for C. neoformans 
 
Inoculum size for E. coli ATCC 25922 was determined to be 3.0 × 10⁸ CFU/mL following preliminary 
experiments to determine chemoattractant (3.7.3.1.i). For C. neoformans, a series of 1:10 dilutions was 
made in RPMI with L-Glutamine (Lonza Group Ltd, Basel, Switzerland) starting with a density of 3.0 
× 10⁸ CFU/mL and ending at 1.0 × 10² CFU/mL (3.6.1.2.i). The Transwell Migration procedure as 
described above (3.7.3) was performed on each of the prepared dilutions. Migrated neutrophils were 
counted using a haemocytometer and enumeration of neutrophils was performed manually according to 
predetermined calculations (Appendix A1). At this point, due to similar size, it was difficult to 
distinguish microscopically between the organism and the migrated neutrophil in the lower chamber of 
the assay using the haemocytometer. Therefore, an alternative method for quantification of migrated 
neutrophils was determined. Using this method (described below), it was determined that the lowest 
concentration at which Cryptococcus caused neutrophil migration was at a density of 1.0 × 10⁶ 
CFU/mL.   
 
iv. Determination of quantification method for migrated neutrophils – The Myeloperoxidase 
(MPO) Human Simple Step ELISA® (Abcam) 
 
Myeloperoxidase (MPO) is an enzyme belonging to the subfamily of peroxidases. A variety of cells 
including neutrophils, lymphocytes [214-216] monocytes, and macrophages [214, 217] are able to 
express this enzyme. The azurophilic granules of neutrophils contain stored myeloperoxidase. When 
the neutrophil is stimulated, exocytosis or degranulation occurs, and the content of the granules is 
released out to the extracellular space [214, 218, 219]. Although various other antimicrobial enzymes 
and proteins are present in these granules, MPO is most abundant and accounts for 5% of neutrophils’ 
dry weight and 25% of  azurophilic granular proteins [214, 220].  A modification to the Boyden 
Chamber method was made by Kristina Somersalo, et al, where the response to chemotaxis was 
determined by measuring myeloperoxidase (MPO) specific to neutrophils and monocytes [213]. They 
found that the MPO Boyden chamber method had the advantages of being faster, was easier to carry 
out and was more objective than the traditional cell count method [213].  
Considering the difficulty encountered when counting cells using the conventional method described 
above (haemocytometer) especially when using Cryptococcus in the preliminary experiments, it was 
decided to measure chemotactic response in this study, by measuring myeloperoxidase in the cell 
extracts after the 30 minute incubation step in the Transwell assay procedure (3.7.3).  
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3.7.3.2 Myeloperoxidase ELISA 
 
i. Principle of the test 
 
In this study, a commercially available Myeloperoxidase (MPO) in vitro SimpleStep ELISA® 
(Enzyme-Linked Immunosorbent Assay) kit (Abcam®, Cambridge, UK) was used. Abcam’s 
Myeloperoxidase (MPO) in vitro SimpleStep ELISA® kit is designed to quantitatively measure human 
myeloperoxidase in various cell culture supernatants, plasma, human serum, urine, milk, saliva, as well 
as cell and tissue extracts. Two antibodies are used in this ELISA, which capture the analyte (MPO) in 
the solution, and these include an affinity tag labelled capture antibody and a reporter conjugated 
detector antibody (Figure 3.2). Immobilization of the capture antibody/analyte/detector antibody-
complex occurs next through immunoaffinity of an anti-tag antibody that coats the well. When 
performing the assay, standards and samples are added first to the designated wells. The antibody mix 
is added next. Following incubation, the wells are washed to ensure removal of any unbound material. 
TMB substrate (3.3′,5.5′-tetramethylbenzidine) is then added and the reaction is catalysed by 
horseradish peroxidase (HRP) during an incubation step. A blue colour change is observed. The reaction 
is stopped by adding Stop Solution, which causes a change in colour from blue to yellow. The colour 
intensity is proportional to the quantity of bound MPO and is measured on a suitable spectrophotometer 
at 450 nm. This is a sensitive assay (the lowest detection limit is 0.026 ng/mL) [221]. 
 
 
Figure 3.2 Myeloperoxidase Assay 
 
 
 
The reaction follows the steps described in 3.7.3.2. The detection enzyme changes the colour of the 
substrate  
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ii. Preparation of reagents, standards and samples 
 
A 96 well plate was used that was provided in the SimpleStep ELISA® (Enzyme-Linked 
Immunosorbent Assay) kit (Abcam, Cambridge, UK). All reagents were equilibrated to room 
temperature (18-25°C) prior to use. The kit contained sufficient reagents for 96 wells (Appendix A5).  
Sample volumes were adjusted as required for the number of wells in each experiment. Serially diluted 
standards were prepared immediately before use. This was constituted in accordance with 
manufacturer’s instructions (Appendix A6). 
 
The samples on which the assay was performed were obtained for each cryptococcal isolate following 
the Transwell procedure described above (3.7.3) i.e. the solution containing migrated neutrophils 
retrieved in individual wells for each cryptococcal isolate. This was centrifuged at 18 000 × g at 4°C 
for 20 minutes. Supernatants were transferred to clean tubes and pellets were discarded. A standard 
1:200 dilution was made for all samples that were assayed. 
iii. Assay procedure 
 
Fifty microliters each of sample or standard was added to appropriately labelled wells. Fifty microliters 
of prepared antibody cocktail consisting of capture and detector antibodies in antibody diluent 
(Appendix A5) was then added to each well. A plate sealer was used to seal the plate and this was 
incubated for one hour on a plate shaker set at 3.6 × g, at room temperature. Each well was then washed 
with 3 × 350 l of 1 × Wash buffer PT (Appendix A5). Care was taken to ensure that all excess liquid 
was removed following the last wash step. One hundred microliters of TMB substrate was added to 
individual wells and incubated for 10 minutes in the dark on a plate shaker set at 3.6 × g. Following 
this, 100 l of Stop Solution was immediately added to each well and the plate was again placed for 1 
minute on a plate shaker to mix the solution. The OD was recorded at 450 nm using a microplate reader 
software (Thermo Fischer Scientific, Massachusetts, USA).  
 
 
3.8 Gene Expression – Quantitation of TLR2 and TLR4 in Human Microglial Cells 
 
 
A human microglial cell line (M059K, ATCC® - CRL-2365ᵀᴹ) was purchased from American Type 
Culture Collection (ATCC), Virginia (USA).  Cells were exposed to cryptococcal isolates for a period 
of two hours.  
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3.8.1 Cell Culture 
 
3.8.1.1 Cell propogation 
 
 
M059K cells (ATCC® CRL-2365ᵀᴹ) as described above (3.8), were regrown from frozen stock as 
advised by ATCC.  Using strict aseptic conditions, the cell suspension was rapidly thawed (not more 
than two minutes) by agitating gently in a water bath at 37°C. The outside of the vial was then 
disinfected with 70% ethanol. Within a laminar flow cabinet the contents of the vial was transferred to 
a 15 mL centrifuge tube, which contained nine millilitres of complete culture medium (Appendix A7). 
This was centrifuged (Heraeus multifuge 3S-R, 2006, Thermo Electron Corporation) at 125 × g for five 
minutes and the supernatant was discarded. This process is recommended to remove cytotoxic 
preservatives such as dimethylsulphoxide (DMSO) that may be present in the freezing fluid. The cell 
pellet was then resuspended in 10 mL of pre-warmed complete culture medium (Appendix A7) and 
transferred into 75 cm³ tissue culture flasks. Pre-warming of culture medium for 15 minutes at 37°C 
was done to ensure that the medium reached the normal pH (7.0 – 7.6) and to prevent cold-shock of the 
cells. Cells were then incubated at 37°C in 5% CO₂ until approximately 90% confluent monolayer was 
obtained. Duration of incubation was determined to be between four to six days to achieve 90% 
confluence. Cells were maintained by refreshing the culture medium every 48 hours. Cell growth was 
observed at 40 × magnification using an inverted light microscope (Nikon Diaphot, Carl Zeis (PTY) 
Limited, Germany). 
 
 
3.8.1.2 Cell counts 
 
 
Cells were enumerated using the “trypan blue exclusion method”. This staining method is one of the 
traditional methods used to do cell viability analyses. Various academic research laboratories and 
industrial biotechnology units use this technique as their standard procedure for this purpose [222]. The 
purpose of this technique is to determine and quantify viable cells in a cell suspension. The test is based 
on the concept that live cells possess cell membranes that are intact and exclude certain dyes, such as 
trypan blue and eosin while this is not the case in dead cells [223]. In this test, 10 μl of cell suspension 
was diluted in 10 μl of phosphate buffered saline (PBS). An equal volume (20 μl) of 0.4 % trypan blue 
was added to this suspension. Ten microliters of the cell-dye suspension was then filled into a Neubauer 
Haemocytometer slide (Appendix A1) with a cover slip and cells were counted using a Coulter counter 
within 3 minutes. Viable cells appeared clear microscopically whilst nonviable cells appeared blue.  
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The number of cells per millilitre was calculated using the following formula:  
 
Number of Viable Cells/mL = total number of viable cells counted × dilution factor (= 4) × 10⁴ 
                                                       number of squares counted (4)                                                                
 
The factor 4 corrects for the dilution with PBS and trypan blue and 104 for the volume. 
 
 
3.8.1.3 Passaging of cells 
 
 
Once a sufficiently confluent monolayer was attained, the monolayer was trypsinised with 0.25% 
Trypsin-0.53 mM EDTA solution (Lonza Group Ltd, Basel, Switzerland). Trypsin is a proteolytic 
enzyme that degrades the extracellular tissue protein matrix, which causes cells to adhere to each other. 
The EDTA is a chelating agent, and removes calcium and magnesium ions, which allow attachment of 
the cells to the flask wall. To achieve this, old medium was removed from the flask and discarded. Cells 
remaining were washed three times with PBS, pH = 7.2 (Appendix B6). One millilitre of trypsin-EDTA 
was added and spread evenly by gently rocking the flask. The trypsin-covered monolayer was then 
incubated for 30 seconds at 37°C to facilitate dispersal. Cells were observed at 40 × magnification under 
an inverted microscope (Nikon Diaphot, Carl Zeis (PTY) Limited, Germany) until the cell layer was 
completely dispersed. Care was taken to expose cells to trypsin for the shortest possible duration (not 
more than five minutes) because trypsin may damage living cells. One millilitre of foetal bovine serum 
(FBS) (Appendix B7) was added to the flask and gently dispersed to counteract the effect of trypsin. 
Cells were gently aspirated and collected into sterile tubes. The cell concentration was adjusted 
according to a predetermined ratio of 1:6. Complete growth medium was added to this suspension and 
seeded to new culture flasks, which were incubated at 37°C in 5% CO₂ until a confluent monolayer was 
obtained.  
 
  
3.8.1.4 Cryopreservation of cells 
 
 
Cryopreservation medium containing 95% complete culture medium and 5% DMSO was added to the 
cell suspension, slowly to prevent cell destruction. A stepwise process was followed to ensure slow 
freezing of cells. This entailed first placing cells at 4°C for one hour followed by a 24-hour storage at  
-20°C. Thereafter, cells were stored at -70°C until required for use.  
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3.8.2 Exposure of cells to Cryptococcus 
 
 
Prepared M059K cells were exposed to cryptococcal isolates for a period of two hours at a ratio of 1000 
cryptococcal cells to 1.0 × 10⁵ M059K cells per well. The Cryptococcus suspension was prepared in a 
series of 1:10 dilutions as previously described (3.7.2.2) to achieve this concentration.  
 
 
3.8.2.1 Confirmation of attachment of C. neoformans to M059K cells 
 
 
M059K cells were regrown in a 75cm³ flask using complete culture medium as described previously 
(3.8.1.1) until confluent. The cells were trypsinized (3.8.1.3) and 100 μl of a 1.0 x 105 cells/mL was 
seeded into the wells of a 96 well flat bottom tissue culture plate and incubated at 37oC in 5% CO2 for 
24 hours. Thereafter, the media was carefully removed from the wells by aspiration and the adherent 
cells were gently washed with PBS, pH = 7.2 three times. Cells were next exposed to 1.0  x 10³  CFU/mL 
of C. neoformans and incubated at 37oC in 5% CO2 for 2 hours. The wells with organism-exposed cells 
were subsequently washed with PBS, pH = 7.2 without disturbing the attached infected cells. These 
cells were fixed with 70% ethanol for 10 minutes in the wells and stained thereafter with 1% crystal 
violet for 5 minutes. The stained cells were visualized under the inverted microscope (Nikon Diaphot, 
Carl Zeis (PTY) Limited) at 100 x magnification. Cells infected with C. neoformans were visualized to 
confirm infection before gene expression assay was carried out. 
 
 
3.8.3 Gene Expression  
 
3.8.3.1.RNA extraction  
 
 
The TaqMan® Gene Expression Cells-to-CT™ Kit (Thermo Fischer Scientific, Massachusetts, USA   
Part No. 4399002) was used to produce DNase I digested cell lysates in accordance with manufacturer’s 
instructions. Reagents were provided in the kit. Cells were exposed to C. neoformans and incubated at 
37oC in 5% CO2 for 2 hours as described previously (3.8.2.1). The culture medium was then aspirated 
and discarded from the wells. One wash of each well with 50 l PBS, pH = 7.2 was done. Without 
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disturbing the cells, the PBS was aspirated and removed from each well. To remove genomic DNA that 
may be present, DNase 1 was diluted into Lysis Solution at a ratio of 1:100. Fifty microliters of Lysis 
Solution with DNase 1 was added to each well and mixed well by gentle pipetting. The lysis reactions 
were incubated for 5 minutes at room temperature following which 5 l of Stop Solution was added to 
each well. This was incubated at room temperature for 2 minutes. RNA lysates were stored at -20oC 
until cDNA synthesis was performed. Six RNA extractions were performed for each sample and these 
were tested separately. 
 
 
3.8.3.2 cDNA synthesis 
 
 
We used the TaqMan® Gene Expression Cells-to-CT™ Kit (Thermo Fischer Scientific, Massachusetts, 
USA, Part No. 4399002) to generate cDNA from RNA lysates. The cDNA synthesis was carried out as 
per manufactures instruction. Under aseptic conditions, 22.5 μl of RNA lysate was added to 27.5 μl 
master mix consisting of 2X RT Buffer, 20X RT Enzyme Mix in nuclease free water and mixed well. 
All steps were performed on ice. The cDNA synthesis was performed on a SimpliAmp™ Thermal 
Cycler (Thermo Fischer Scientific, Massachusetts, USA, Cat no. A24811) which was programmed as 
shown in Table 3.2. 
 
 
TABLE 3.2: Thermal cycle programme for reverse transcription 
    
sequence no. of cycles temperature time (minutes) 
reverse transcription (RT) 1 37°C 120 
    
RT inactivation  1 95°C 5 
    
hold 1 4°C indefinite 
 
 
 
The total cDNA concentration was quantified using a Nanodrop 1000 spectrophotometer (Thermo 
Fischer Scientific, Massachusetts, USA) and samples were only used if the optical density at 260 nm 
(OD260)/OD280 ratio was 1.8 or higher. 
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3.8.3.3 Real Time Polymerase Chain Reaction  
 
 
Quantitative real time Polymerase chain reaction (PCR) was performed on the following genes, 18S  
(Thermo Fischer Scientific, Massachusetts, USA, Cat no: Hs99999901_s1 18S), TLR2 (Thermo Fischer 
Scientific, Massachusetts, USA, Cat no: Hs02621280_ s1 TLR2) and TLR4 (Thermo Fischer Scientific, 
Massachusetts, USA, Cat no: Hs00152939_ m1 TLR4). TaqMan probes were specifically designed 
from highly conserved regions of the genes. Each cDNA sample was diluted 1:10 for real time PCR 
analysis. Each PCR reaction comprised of 0.5 l FAMᵀᴹ labelled probe primer mix for individual 
targets, 5.0 l TaqMan® Gene Expression Master Mix (2X) (Thermo Fischer Scientific, Massachusetts, 
USA, Part No. 4399002), 1.0 μl cDNA and 3.5 l water resulting in an end volume of 10 l.  Reactions 
were run on a Quant Studio 5 real time PCR machine (Thermo Fischer Scientific, Massachusetts, USA, 
Cat no:  A28140) with one cycle at 95 ˚C for 10 minutes, followed by 45 cycles consisting of 
denaturation at 95 ̊ C for 15 seconds, and annealing for one minute at 60 ̊ C.  Detection of the fluorescent 
products was carried out at the end of the 60 ˚C annealing period.  Standard curves were made for each 
gene from a pool of cDNA from every sample (Figures 3.3, 3.4, 3.5). Serial dilutions of cDNA from 
RNA lysates were made for each target gene. Standard curves were made from these and used for 
quantitative analysis. All samples where run in duplicate. Data is represented as normalized gene 
expression to 18S. 
 
 
 
Figure 3.3 Amplification Plot and Standard Curve of the 18S Gene 
 
Amplification Plot of 18S                                                    Standard Curve for 18S 
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Figure 3.4 Amplification Plot and Standard Curve for the TLR2 Gene 
Amplification Plot of TLR2                                                   Standard Curve for TLR2 
 
   
                                                                                                  
 
 
 
Figure 3.5 Amplification Plot and Standard Curve for the TLR4 Gene 
 
Amplification Plot of TLR4                                           Standard Curve for TLR4      
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3.9 Statistical Analysis 
 
 
All experiments were done in triplicate. The distribution of cell count and neutrophil data were 
summarized using medians and interquartile ranges. Mann-Whitney non-parametric tests were used for 
two group comparisons and Kruskal-Wallis for more than two groups.  Numeric variables such as CSF, 
capsule size and opening pressure were also categorized and chi square tests or Fisher’s exact were used 
to compare sub-groups.  The association between two number variables was examined using scatter 
plots and Spearman’s correlation coefficient.  Stata v13 statistical software was used in the analysis. 
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CHAPTER 4 - RESULTS 
 
 
4.1 Description of Clinical Data 
 
 
Seventy-one participants were enrolled in the study. Cryptococcus neoformans was identified in the 
CSF of all 71 patients. The general clinical parameters indicative of meningitis (fever, headache and 
neck stiffness) were recorded (Table 4.1.1). The commonest clinical finding was headache (71 patients), 
followed by neck stiffness (48 patients). Only 15 patients presented with fever. The mean age was 35 
years with a range of 18 – 62 years. There were 11 more male than female patients (41 vs 30). Fifty-
nine patients had positive Gram stain microscopy for Cryptococcus whilst all patients had an initial 
Cryptococcal Latex Agglutination Test (CLAT) positive.    
 
TABLE 4.1.1: Clinical and laboratory parameters of 71 patients presenting with meningitis 
                         at the time of admission  
  
  no. (%) 
Glasgow coma scale = 15  60 (85) 
headache  71 (100) 
fever  15 (21) 
neck stiffness  48 (68) 
papilloedema  0 (0) 
cryptococcus seen on Microscopy  59 (83) 
qualitative CLAT titre 71 (100) 
 
 
At the baseline diagnostic lumbar puncture (LP), 65 patients had CSF opening pressure (OP) measured 
(Table 4.1.2). Thirty-nine of these patients had an opening pressure >20 cm H₂O. CSF chemistry was 
slightly abnormal with a median protein of 0.83 g/L (IQR = 0.43 – 1.35) and glucose median of 2.1 
mmol/L (IQR = 1.2 – 2.6). The CSF neutrophil count was within the normal range (IQR = 0 – 4 
cells/mL). CSF lymphocytes however were elevated at baseline with a median of 21 cells/mL (IQR = 
8 – 84). Notably, the blood neutrophil counts of all patients were within the normal range (median = 
4.29; IQR = 2.58 – 6.10). As a means to determine the amount of shed capsular material in CSF and 
serum, two-fold serial dilutions of each specimen was done until the endpoint of CLAT antigen 
positivity was reached.  The median CSF and serum CLAT titres were both 2048, however the IQRs 
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were different (CSF IQR = 9256 – 8192; serum IQR = 256 – 4096). Raw data for CLAT titre 
investigations are displayed in Appendix C1. The average capsule size was measured as described 
earlier (3.6.1). Raw data for determination of capsule size is available in Appendix C2. Measurement 
of capsule thickness was performed on Cryptococcus cells isolated from the 65 culture positive CSF 
specimens. These organisms were all passaged once after initial isolation (3.6.1). The median capsule 
thickness was 1.2 μm (IQR = 1.04 – 1.39). 
 
 
TABLE 4.1.2: Baseline blood and cerebrospinal fluid (CSF) investigations of 71 patients 
                         presenting with meningitis 
   
  no. tested median (IQR) 
blood CD4  70 39.5 (14 - 96) 
blood neutrophils *  62 4.29 (2.58 - 6.10) 
serum CLAT titre  71 2048 (256 - 4096) 
  
 
CSF opening pressure  65 22 (16 - 29) 
CSF protein  71 0.83 (0.43 - 1.35) 
CSF chloride  70 117 (113 - 121) 
CSF glucose  71 2.1 (1.2 - 2.6) 
CSF neutrophils **  70 0 (0-4) 
CSF lymphocytes **  70 21 (8 - 84) 
CSF RBC **  70 0 (0 - 30) 
CSF CLAT titre  71 2048 (9256 - 8192) 
average capsule size ***  65 1.2 (1.04 - 1.39) 
   
CLAT: cryptococcal latex agglutination test;  * × 10⁹/L; ** cells/μl; *** μm 
 
 
4.2 Association between CSF neutrophil and blood neutrophil count 
 
 
It is known that cryptococcal meningitis is characterized by a relative paucity of neutrophils in the CSF 
as compared to that in bacterial meningitis [3-5, 56, 201]. Blood neutrophil and CSF neutrophil counts 
of patients were obtained at time of admission and comparisons were made (Table 4.2.1). Complete 
data (which included blood neutrophil and CSF neutrophil counts) were available for 62 patients. The 
majority (47) had a CSF neutrophil count below five cells per microliter (cells/μl) of who 39 patients 
had no neutrophils in the CSF at all. Only 15 patients had a CSF neutrophil count of > 5 cells/μl. Of the 
47 patients with CSF counts below five cells/μl, 40 (85.11%) had blood-neutrophil counts at the higher 
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end of the normal range (2 - 7 ×10⁹ cells/L). Nine patients had an elevated blood neutrophil count. Eight 
of these had CSF neutrophil counts of < 5 cells/μl. An association was noted between CSF neutrophil 
and blood neutrophil count where a lower CSF neutrophil count appeared to be associated with higher 
blood neutrophil count. However, this was not statistically significant (p = 0.37).  
 
Table 4.2.1: Comparison between blood neutrophil and CSF neutrophil count 
     
CSF neutrophils (cells/μl) 
no. (%) of patients with blood neutrophils *: Total 
<2 2 to 7 >7   
<5 7 (15) 32 (68) 8 (17) 47 
>5 1 (7) 13 (87) 1 (7) 15 
Total 8 (13) 45 (73) 9 (62) 62 
     
* x 10⁹ cells/L     
 
 
4.3 Association between clinical parameters and neutrophil count, cryptococcal capsule 
size and shed cryptococcal capsular material  
 
 
In keeping with meningitis, all of the study patients presented with headache as the predominant clinical 
symptom.  There were however only 15 patients who presented with fever. The association between 
fever and total CSF and blood neutrophil counts, cryptococcal capsule size and cryptococcal shed 
antigen (CSF CLAT titre) were further investigated (Table 4.3.1). Nine of the 15 patients with fever 
had a CSF neutrophil count of < 5 cells/μl (p=0.05). Forty-six patients presented without fever. Of 
statistical significance was that patients with fever had a higher CSF neutrophil count (p = 0.003). In 
contrast with the CSF neutrophil-count, those patients who presented with fever had a lower blood-
neutrophil count. This displayed a borderline significance (p = 0.08). However, the blood neutrophil 
count remained within the normal range in all patients with or without fever. The capsule size of 
cryptococcal cells isolated from patients with fever tended to be smaller than in patients without fever, 
however, there was no statistical significance (p = 0.18). Similarly, the comparison between shed 
capsular material in the CSF of patients with fever and those without fever showed no significant 
difference (p = 0.86).  
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Table 4.3.1: Association between fever and neutrophil count, cryptococcal capsule size and  
                     shed cryptococcal capsular material in 71 patients presenting with meningitis 
     
  no. of patients  with:  
 no. of 
patients 
fever (n=15) no fever (n=55) p-value 
CSF neutrophils > 5 cells/μl                                 15 6 9 0.05 
median (cells/μl) CSF 
neutrophils (IQR) 
70 4 (0 - 16) 0 (0 - 2) 0.003 
median  (×10⁹ cells/L) blood 
neutrophils (IQR) 
62 3.47 (2.37 - 4.46) 4.36 (2.94 - 6.25) 0.08 
median (μm) capsule size (IQR) 65 1.06 ( 1.02 - 1.33) 1.23 (1.06 - 1.46) 0.18 
median CSF CLAT titre (IQR) 71 2048 (512 - 8192) 2048 ( 256 - 8192)   0.859 
     
CLAT: cryptococcal latex agglutination test   
 
All 71 patients presented with headache as a common clinical symptom. Fifteen patients with headache 
had fever and 48 had neck stiffness (Table 4.3.2). Of all the patients with headache, 55 had CSF 
neutrophil counts of ≤ 5 cells/μl of which 46 had no neutrophils at all in the CSF. (There was missing 
data (CSF neutrophil count) for one patient). 
 
 
Table 4.3.2: Headache in association with six other parameters in 71 patients presenting 
                     with meningitis  
   
  
no. of 
patients 
no. (%/IQR) of patients with: 
fever  71 15 (21) 
neck stiffness 71 48 (68) 
CSF neutrophils: 70  
≤5 (cells/μl)  median CSF neutrophils  55 0.0 (0 -0) 
>5 (cells/μl) median CSF neutrophils  15 16 (8- 60) 
median CSF neutrophils  70 0.0 (0 - 4) 
median capsule size(μm)  65 1.198 (1.034 - 1.418) 
median CSF CLAT titre   71 2048 (256 - 8192) 
median blood neutrophils (×10⁹cells/L)  62 4.29 (2.58 - 6.13) 
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4.4 Shedding of cryptococcal capsular material: Effect on opening pressure, CSF      
neutrophil count and capsule size 
 
 
Shed capsular material was quantified as described previously (3.4). Twenty-five CSF specimens had 
a CLAT titre below 512; 25 had a titre between 1024 and 4096 and 21 samples had a titre ≥ 8192. Raw 
data for CSF CLAT titre is shown in Appendix C1. The CSF opening pressure appeared to decrease 
with increasing CLAT titre (Fig 4.1). There was a tendency for the average capsule size to decrease 
with increased amount of shed capsular material. Spearman’s correlation co-efficient determined that 
this was not statistically significant, however (Spearman’s rho = − 0.2) (Fig 4.2).  
 
Figure 4.1: Shed Crytpococcal Capsular Material: Association with Opening Pressure 
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Figure 4.2: Shed Crytpococcal Capsular Material: Association with Capsule size 
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There was a significant association with shed capsular material (CSF CLAT titre) and number of 
neutrophils in CSF (Table 4.4.1). With a higher CSF CLAT titre there were significantly more patients 
with lower CSF neutrophils (p = 0.03, Spearman’s rho = − 0.3).  
 
TABLE 4.4.1: Shed capsular material in relation with CSF neutrophils, opening   
                         pressure and capsule size   
     
     
  
CSF CLAT titre 
p-
value 
    <1000 >1000   
CSF neutrophils (cells/μl) ≤5 16 39 0.03 
 >5 9 6  
opening pressure (cmH₂0) ≤20 8 18 0.15 
 >20 15 24  
median capsule size 
(IQR)   
1.30 (1.08 - 1.45) 1.11 (1.04 - 1.37) 0.14 
     
CLAT: cryptococcal latex agglutination test  
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4.5 Capsule thickness and its association with opening pressure, blood and CSF     
neutrophils and CSF CLAT titre 
 
 
The capsule of C. neoformans is a known virulence factor. Previous studies have shown that the capsule 
can change in size in response to environmental conditions. In this study, capsule size was measured as 
described previously (3.6.1). Raw data for determination of capsule size is shown in Appendix C2. 
Average capsule size ranged between 0.73 μm – 2.46 μm and based on the size of the capsule patients 
were divided into four groups for further analysis (Table 4.5.1). The majority of cryptococcal cells (n = 
54) had capsule sizes that ranged between one and two micrometers respectively. The opening pressure 
was elevated in all four groups with the highest opening pressures recorded in those patients with 
cryptococci with an average capsule size > 2 m. CSF neutrophil counts were lowest in this last group 
with cells that had capsule size > 2 m and highest in patients with cryptococcal cells with capsule size 
< 1 m. Blood neutrophil counts were similar in all four groups. However, like CSF neutrophil counts, 
blood neutrophil counts were also lowest in the patients whose cryptococci had a capsule size of > 2 
m. Those CSF samples with C. neoformans cells that had a capsule size > 2 m also displayed the 
lowest shed cryptococcal capsular material (average CSF CLAT titre = 768) compared to the other three 
groups. 
 
 
TABLE 4.5.1 : Capsule size in relation to opening pressure, blood and CSF neutrophils  
                          and CSF CLAT titre    
      
average capsule 
size (μm) 
no. of 
patients 
average (SD) 
opening pressure 
(cmH₂0) 
average (SD) 
CSF 
neutrophils 
(cells/μl) 
average (SD) 
blood 
neutrophils 
(×10⁹ cells/L) 
median (IQR) 
CSF CLAT titre 
<1  9 23.44 (10.41) 13.78 (36.16) 5.23 (3.45) 
2048 (1024 - 
8192) 
1 - 1.19  24 22.86 (12.90) 9.0 (22.85) 4.34 (1.92) 
4096 (768 - 
12288) 
1.2 - 2.0  30 22.24 (10.12) 4.87 (14.46) 4.35 (2.53) 
1024 (256 - 
4096) 
>2  2 25.50 (0.71) 2.0 (2.83) 3.73 (2.03) 768 (512 - 1024) 
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Figure 4.3: Cryptococcus Capsule size in Relation to CSF Neutrophil Count 
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In this analysis, the capsule size is larger in those patients with lower CSF neutrophil counts (Table 
4.5.2). However, this is not statistically significant (p = 0.28). There was no relationship between 
capsule size and blood neutrophils. Blood neutrophils were essentially within the normal range in the 
study group. 
 
TABLE 4.5.2: Capsule size in relation to neutrophil count 
 
 
    
  
  
no. of 
patients 
median (IQR) 
capsule size (μm)  
p-value 
CSF neutrophils *: ≤5 52 1.21 (1.06 - 1.41) 0.28 
 >5 13 1.06 (1.02 - 1.39)  
Blood neutrophils **: <2 8 1.51 (1.12 - 1.81) 0.22 
 2 to 7 41 1.10 (1.03 -1.33)  
  >7 8 1.26 (1.03 - 1.45)   
* cells/μl ; ** x 10⁹ cells/L     
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4.6 Neutrophil chemotaxis inhibition 
 
 
Various explanations are presented in the literature regarding the possibility of inhibition of neutrophil 
chemotaxis in the CSF. In this study, chemotaxis experiments were conducted as described earlier (3.7) 
and chemotaxis inhibition was calculated. Raw data is displayed in Appendix C3. There was no 
inhibition by 21 cryptococcal isolates while 44 displayed chemotaxis inhibition (Table 4.6). The amount 
of shed cryptococcal capsular material (CLAT titre) was higher in the group that displayed chemotaxis 
inhibition (but not statistically significant). Capsule size was similar in both groups. The number of 
neutrophils in the CSF was significantly higher in the group that displayed chemotaxis inhibition (10.82 
vs 0.67 cells/mL respectively; p = 0.04). 
 
 
TABLE 4.6: Chemotaxis inhibition in relation to CSF CLAT titre, capsule size   
                      and CSF  neutrophils   
     
          average (SD) of patients with: 
chemotaxis  
no. of 
patients: 
median (IQR) CSF 
CLAT titre  
 capsule size (μm)  
CSF neutrophils 
(cells/mL)  
     
activation 21 1024 (512 - 4096) 1.27 (0.30) 0.67 (1.59) 
inhibition 44 4096 (384 - 8192) 1.26 (0.37) 10.82 (25.38)   
  
   
CLAT: cryptococcal latex agglutination test   
 
 
4.7 Expression of TLR2 and TLR4 genes in human microglial cells  
 
 
In this study, we attempted to show TLR2 and TLR4 gene expression induced by the individual strains 
of Cryptococcus in human microglial cells. This was performed on 64 C. neoformans isolates. Gene 
expression was performed as described earlier (3.8.3). Forty-five (70 %) of these isolates displayed 
downregulation for TLR2 and 19 showed upregulation (Table 4.7.1). Capsule size did not vary 
remarkably in both these groups. Neutrophil counts were higher in those CSF specimens that grew 
cryptococci that upregulated TLR2 expression more than 10 times, and was lower in those specimens 
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that showed downregulation, but this finding is not statistically significant. The amount of shed capsular 
material was also similar in all the groups. 
 
TABLE 4.7.1: Expression of TLR2 genes in relation to average capsule size, CSF  
                         neutrophils and CSF CLAT titre   
     
 
TLR2/18S no.of 
patients  average (SD) capsule 
size (μm)  
average (SD) CSF 
neutrophils (cells/μl)  
median (IQR) CSF 
CLAT titre  
 
<1  45 1.30 (0.38) 7.06 (19.82) 4096 (512 - 8192)  
1.0 - 10  12 1.27 (0.30) 5.67 (18.39) 1024 (288 - 6144)  
 >10  7 1.15 (0.18) 13.71 (36.28) 4096 (256 - 32768) 
 
 
 
TLR4 gene expression was similar to TLR2 regarding upregulated (n = 21) and downregulated (n = 43) 
gene expression (Table 4.7.2). There was a strong correlation (Spearman’s rho = 0.9) between 
expression of the two genes. The average capsule size did not display much variation among the 
different groups. The CSF neutrophil counts however were lower in the isolates that showed 
upregulation above 10x and there were in fact zero cells per milliliter in this small group. This was not 
statistically significant. Shed capsular material was similar in the different groups. 
Raw data for expression of TLR2 and TLR4 is shown in Appendix C4. 
 
 
TABLE 4.7.2: Expression of TLR4 genes in Relation to Average Capsule size, CSF  
                       neutrophils and CSF CLAT titre   
      
TLR4/18S no.of 
patients  average (SD) 
capsule size (μm)  
average (SD) CSF 
neutrophils 
(cells/μl)  
median (IQR) 
CSF CLAT titre  
 
<1  43 1.31 (0.38) 6.70 (20.27) 4096 (512 - 8192)  
1.0 - 10  15 1.18 (0.32) 12.93 (28.21) 1024 (512 - 8192)  
>10  6* 1.21 (0.12) 0.0 (0.0) 1453 (64 - 8192)  
*5 of these had the same value for TLR2 expression   
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CHAPTER 5 – DISCUSSION AND CONCLUSION 
 
Cryptococcal meningitis is an important opportunistic infection especially in the immunocompromised 
patient. It is well known that cryptococcal meningitis characteristically has a relative paucity of 
polymorphonuclear neutrophils (PMN) in the CSF when compared to bacterial meningitis [3-5]. This 
is despite evidence that the capsular material induces production of the early proinflammatory cytokines 
IL-1β and TNF-α by peripheral blood PMNs and monocytes [3, 36, 224]. Mouse model studies 
previously showed that the inhibition of PMN infiltration was mainly due to major capsule component 
GXM [225]. Several studies have attempted to determine the mechanisms involved in regulating 
passage of leucocytes through endothelial cells yet the mechanism by which signaling in brain 
inflammation occur, is still unclear [3]. In this study, we hypothesized that the capsular material 
interfered with neutrophil chemotaxis and that this had an inverse impact on severity of disease. Few 
studies have been done on human infection and therefore this study focused on human infection and 
effect on host inflammatory response. Similar to previous studies, our study shows typically few 
mononuclear cells and virtually no PMNs in patients’ CSF and interestingly, all patients’ blood PMNs 
were within the normal range that is, neither elevated nor decreased. Furthermore, we observed that a 
low CSF neutrophil count was associated with a higher blood neutrophil count although this was not 
statistically significant. 
 It is important to note that the sample size in this study had to be considerably reduced (by 70%) due 
to a general decrease in patients presenting with crytpococcal meningitis to hospital. The recruitment 
of patients for the study was therefore significantly compromised. A possible explanation for this drastic 
decrease could be the fact that highly active antiretroviral therapy (HAART) was introduced to patients 
infected with HIV, and studies show that there is a positive impact of HAART to patients with 
crytpococcal infection especially in Western countries [226, 227]. 
Although there is no severity of disease score for patients with cryptococcal meningitis, a trend in 
clinical parameters was evident in these patients in keeping with the literature. Of the clinical parameters 
measured, headache was the predominant clinical symptom in all patients followed by neck stiffness. 
Fever occurred in only a fraction of the patients. These findings are consistent with other studies that  
describe the clinical course of cryptococcal meningitis as subacute or chronic with headache being a 
predominant finding [228, 229]. In fact, it is known that patients with AIDS may even remain 
asymptomatic early in the disease process and that the classic symptoms of meningitis (headache, 
photophobia and meningism) may be absent [230, 231]. Furthermore, it has been observed that 
cryptococcal encephalitis may remain undiagnosed due to poor inflammation at the site of infection 
[139, 232].  Vaidhya et al identified fever, headache and neck stiffness respectively as the predominant 
symptoms in their cohort, which differs from the findings in this study where fever occurred in only a 
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small fraction (21%) of patients [96]. Clinical signs such as papilloedema, hydrocephalus and focal 
seizures during cryptococcal meningitis is a common occurrence in immunocompetent patients [228, 
233]. This study population included only immunocompromised patients and consistent with this 
observation, none of the patients showed signs of papilloedema. More than 50% of patients also showed 
evidence of mildly raised intracranial pressure (ICP) with a median opening pressure of 22 cmH₂0. This 
finding is noteworthy considering that in this study the opening pressure was recorded only at the second 
lumbar puncture where it is performed routinely to reduce intracranial pressure. Raised intracranial 
pressure is a common complication of cryptococcal meningitis and contributes to morbidity and 
mortality [234, 235]. It is not clearly understood what the causes of raised intracranial pressure in 
cryptococcal meningitis are, however, some hypotheses are that it may be related to impaired CSF 
reabsorption caused by the organism or perhaps its shed polysaccharide capsule [234, 236]. It was also 
noted in this study that the CSF chemistry (protein and glucose) was only slightly abnormal. This relates 
to previous studies that describe clear differences in CSF chemistry between cryptococcal meningitis 
(moderate elevation in protein and moderate decrease to normal glucose) and bacterial meningitis (high 
protein and low glucose) [228, 237].  
Significantly, patients who presented with fever had a higher CSF PMN count compared to patients 
with no fever. Patients with fever also had a lower blood PMN count. Cellular components of the innate 
immune system (including neutrophils) form part of the first line of defense in cryptococcosis [119]. 
These cells recognize and phagocytose the yeast resulting ultimately in their degradation. Fever is often 
a manifestation of an aggressive inflammatory response [238]. This was confirmed in our finding that 
patients who mounted a neutrophil response presented clinically with fever. The concept of the 
association of fever with leucocyte infiltration dates as far back as the 19th century [239]. The 
hypothalamus in the brain regulates and maintains normal body temperature. The febrile response is a 
prominent component of various inflammatory and immunologically mediated diseases [239]. These 
infections, including bacterial, viral and fungal infections, may result in the production of pyrogens that 
alter the “thermostat setting” of the hypothalamus to raise body temperature leading to fever. Pyrogens 
may be both exogenous as well as endogenous. Cytokines that are known to be intrinsically pyrogenic 
are IL-1α, IL-1β, TNF-α, TNF-β, IFN-γ, and IL-6  [239]. Following CNS invasion by C. neoformans, 
the microglial response is critical. Microglial cells together with astrocytes recognize fungal PAMPS. 
During fungal antigen exposure, cytokines, which include the pyrogenic cytokines (IL-1β, TNF-α, IFN-
γ, and IL-6) recruit peripheral CD4 and CD8 T-cells, peripheral macrophages, and neutrophils, which 
are then able to seed into the CNS [171].  In addition, the literature demonstrates that neutrophils also 
produce and express various cytokines either constitutively or upon activation by micro-environmental 
stimuli [240]. The pyrogenic cytokines are known examples of cytokines that neutrophils can 
potentially express and/or produce [240]. The relationship between fever and PMN counts in CSF or 
blood in cryptococcal meningitis has not been explored previously. Fernandes et al noted that there was 
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a positive correlation between fever and increased capsule thickness [238]. We found no significant 
correlation between fever and phenotypic characteristics of Cryptococcus such as the capsule thickness 
or the amount of shed capsule.  
The polysaccharide capsule of C. neoformans is one of its most important virulence factors and plays a 
role in evading phagocytosis as well as regulating the immune response [39, 45-49]. Some studies 
suggest that the ability of phagocytes to clear the organism inversely relates to the capsule size [36, 37]. 
The phenomenon of capsular enlargement during infection is important as this has an effect on the size 
of the cell thus creating a problem for phagocytosis [101, 109, 241]. Various studies suggest an 
association between increased capsule size and resistance to phagocytosis [241-243]. In particular, one 
compartment in which induction of capsule increase took place, although less efficiently than in the 
lung, was found to be the brain [241, 244]. Littman demonstrated that the capsule size was quite variable 
and depended on the organ affected [241, 245]. Charlier et al reported that tissue invasion was 
associated with changes in size and composition of the organism’s capsule in the brain of AIDS patients 
with both acute and chronic meningoencephalitis [1]. In our study, the capsule size ranged between 0.7 
μm and 2.5 μm. The normal size of the cryptococcal capsule ranges between 2.0 – 4.0 μm, which 
indicates that the capsule size was not enlarged in the study group. There were however, a large number 
(97%) that expressed a capsule size below the normal range. A possible explanation for this is that the 
organisms were isolated from CSF on sheep blood agar (3.3) and passaged once in vitro on Brain Heart 
Infusion Agar plates supplemented with 10% horse blood (3.6) before the capsule measurements took 
place. In an in vitro murine study, Dykstra et al observed that cryptococcal cells in diseased tissue had 
large capsules, but when grown on ordinary media such as Sabouraud glucose agar, there was notable 
variation in capsule size [246]. They postulated that capsule size decreased in high osmolarity media 
and enlarged in media of low osmolarity. Furthermore, they suggested that although cells may produce 
the same amount of capsular material despite osmolarity, the volume occupied in high osmolarity media 
could possibly be less due to shrinkage [246]. In our study, the capsule size was larger in patients with 
lower CSF neutrophil counts, although this was not statistically significant. This is in keeping with 
previous findings that the capsule suppresses immune cell infiltration into the CNS [247, 248]. Our 
study also suggests that patients’ whose isolates had larger capsules also had higher CSF opening 
pressures. Robertson et al demonstrated that patients who had C. neoformans infection had a greater 
chance of having raised intracranial pressures and diminished CSF inflammatory response when 
infecting strains produced larger capsules [248]. This finding corroborates an earlier study in a rat model 
that showed that capsular phenotype influences raised intracranial pressure [248, 249]. 
A major polysaccharide component of the Cryptococcus capsule is glucuronoxylomannan (GXM), 
which is shed freely from the capsule and accumulates in body fluids and tissue of patients during 
infection [2, 151]. In disseminated cryptococcal infection, there are high serum and CSF titres of GXM 
in affected patients and this has been associated with disease progression as well as a diminished 
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inflammatory response [3, 151, 250]. In this study, we quantified shed capsular material in individual 
patient CSF samples and analyzed the effect of shed capsular material on CSF neutrophil count as well 
as on CSF opening pressure and capsule size. There was a significant association with shed capsular 
material and number of neutrophils in CSF. With a higher CSF CLAT titre there were significantly 
more patients with lower CSF neutrophils (p = 0.03). Various explanations have been described in the 
literature regarding the possibility of inhibition of chemotaxis in the CSF. One such explanation is a 
phenomenon called cross desensitization of the IL-8 receptor which describes the relationship of FMLP 
and C5a (also neutrophil chemoattractants) to IL-8 [5, 204]. In that study, rapid desensitization for IL-
8 was shown to have occurred when PMNLs were previously exposed to the chemoattractants IL-8 
itself, C5a or FMLP. Receptor phosphorylation and IL-8 receptor internalization was believed to be the 
mechanism involved during this process [204]. In another study, GXM was observed to inhibit 
polymorphonuclear leucocyte (PMNL) adhesion to activated endothelial cells in a concentration 
dependent manner [56]. They used a static adhesion assay and found that GXM exerts this action by 
affecting both PMNs and endothelial cells [56]. Another possibility for the paucity of leucocytes 
described in the literature was that although production of interleukin-8 (IL-8) occurred in the CSF of 
patients with cryptococcal meningitis, the circulating GXM was downregulating recruitment of 
leucocytes, thus leading to impaired migration of leucocytes into the CSF [205, 206]. 
In this study, chemotaxis experiments were performed on individual isolates of Cryptococcus obtained 
from patients CSF to determine the extent of inhibition of neutrophil chemotaxis. Close to 70% of 
isolates displayed chemotaxis inhibition. Although this was not statistically significant, the amount of 
shed cryptococcal capsular material was higher in the group that displayed chemotaxis inhibition. This 
is in keeping with several previous studies that showed evidence of capsular material especially GXM 
inhibiting leucocyte migration [3-5, 56, 57].  Lipovsky et al, further determined that the different GXM 
serotypes varied in their ability to induce production of IL-8 [5]. They also found that most clinically 
important isolates of C. neoformans were of the serotype A. They concluded in their study that the 
cryptococcal polysaccharide capsule inhibited neutrophil migration toward IL-8 in both GXM serotypes 
A and D [5]. The number of neutrophils in the CSF was significantly higher in the group that displayed 
chemotaxis inhibition (p=0.04). This finding is interesting because it was expected that with chemotaxis 
inhibition, there would be a lower number of neutrophils in the CSF. This is also contrary to the finding 
that fewer neutrophils were found in the CSF of patients whose cryptococcal isolates shed more capsular 
material in the CSF. A possible explanation for this could be that there was a small percentage of 
patients (7%) in this group that had very high neutrophil counts (above 60 cells/mL) in their CSF, which 
may have influenced the average neutrophil count in this group. When this group (7%) was excluded 
and the average neutrophil count in the CSF was recalculated, this observation turned out not to be true. 
The presence of leucocytes is regulated through chemotaxis. Chemotaxis depends on chemokine 
production at the site of infection and the level of expression of corresponding chemokine receptors on 
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the migrating cells. Chemokines are major mediators of leucocyte recruitment into infection sites, 
including infections with C. neoformans [202]. In the brain, microglial cells are known sources of not 
only IL-8,  but also other chemokines such as IP-10, MIP-1, MIP-1, RANTES, KC, and MCP-1 
[203]. Therefore, a further explanation for this discrepant finding could be the varying effects of 
chemokines at the site of infection. Chemokines were not measured in this study and this finding 
stimulates further research. 
Capsule size was similar in both groups (chemotaxis inhibition and no inhibition) although interestingly, 
there was a tendency for the average capsule size to decrease with an increased amount of shed capsular 
material. This is in accordance with studies that showed how the capsule of C. neoformans responded 
to various environmental factors [251-253]. Larger capsules were related to greater production of 
polysaccharides, a greater and more extensive assembly of polysaccharide, and also less shedding of 
capsule [251]. This could imply that with greater shedding of capsular material, the capsule size would 
also be smaller, as was observed in our study. In a recent study by Fernandes et al, cryptococcal capsule 
size was found to differ between individual isolates, genotypes, as well as species [238]. They have also 
stated that it is not clear whether a large capsular phenotype enhances the overall virulence of 
Cryptococcus. However, a finding in their study was that capsule size correlated strongly with yeast 
cell size, and as such, the possibility existed that capsule alone has less significance than overall size of 
the cell [238].  
Microglial cells, which are phagocytic cells within the central nervous system, along with meningeal 
and perivascular macrophages, make up the first line of defence in the brain during CNS infections 
[168-170]. These cells are major regulators of the innate immune response because they express Toll-
like receptors (TLRs) which can identify pathogen associated molecular patterns (PAMPs) [170, 173, 
174]. Chemokines are produced when TLRs recognize specific microbes. For C. neoformans, TLR2 
has been identified as the most important TLR [6, 7, 175]. It has been shown that TLR2 and TLR4 
recognize cryptococcal capsular component GXM [170, 175]. GXM bound to both TLR2 and TLR4 
with the co-receptor CD14 but it was unable to activate the MAPK (mitogen-activated protein kinase) 
pathway and produce TNF-α [170, 175]. Although increasing interest in expression of TLRs is 
becoming evident, little information is available on expression and function of TLRs in the CNS 
microglial cells [7]. Some data is becoming available on TLR expression in rodent CNS, however little 
information exists on TLR expression in human microglial cells [7]. 
 In this study, we measured TLR2 and TLR4 gene expression induced by the individual strains of 
Cryptococcus in human microglial cells. Both TLR2 as well as TLR4 were expressed similarly in 
microglial cells by individual cryptococcal isolates. This concurs with earlier studies that associated 
both TLRs with cryptococcal infection [170, 175]. Biondo et al, however, concluded in their study, that 
TLR2 but not TLR4 contributed to anti-cryptococcal defenses [164]. We showed that exposure to the 
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majority (nearly 70%) of cryptococcal isolates induced downregulation for both TLRs in the glial cells 
and only a small proportion resulted in upregulation. This supports one of our research questions that 
downregulation of neutrophil chemotaxis occurs at the level of TLR expression.  
In keeping with this finding was that neutrophils were lower in the CSF specimens where there was 
downregulation (TLR4/18s <1) of the TLR4 genes in human microglial cells. This was however not 
true for TLR2 gene expression.  Netea et al reported the effect of TLRs in another fungal pathogen 
(Candida albicans) [254, 255]. Their experiments in mice which express  defective TLR4 genes showed 
impaired neutrophil recruitment to the site of infection [254]. Further studies on the fungal pathogen C. 
albicans showed conflicting results with TLR2, which displayed either protective or harmful effects on 
the pathogen [167, 255, 256]. Furthermore, various research on Aspergillus fumigatus described the 
function of TLR2, TLR4 and MyD88 in neutrophil activation and cytokine secretion [255, 257-259]. 
Redlich et al stimulated microglial cells with various TLR agonists and found that this enhanced 
phagocytosis of fungi as well as bacteria [170, 260, 261]. They have also shown that a role of TLRs in 
the phagocytosis of C. neoformans requires the MyD88 signaling cascade, which is used by all TLRs 
except TLR3. Although there is some evidence of the role of TLRs in the early immune response to 
fungal infection, none of these studies shows clarity on the role of TLRs and their effect on neutrophil 
activation in cryptococcal infection in humans. In our study there is a possible association between 
neutrophil recruitment and TLR expression in human microglial cells, although further studies are 
needed to confirm this.  
There was no significant association between the amount of shed capsular material and expression of 
TLRs in our study. Several studies have reported the ability of capsular GXM to activate a TLR-
mediated immune response [165, 175, 176, 262].  GXM has been shown to interact with both TLR2 
and TLR4, which is believed to influence response to cryptococcal infection [164, 165, 175, 263]. In 
our study, a possible explanation for the lack of an association could be the small sample size. Further 
studies would be beneficial to confirm this observation. 
In conclusion, there is increasing interest and research focusing on understanding the pathogenesis of 
cryptococcosis. Most of this research has thus far, focused on animal models. This study is among the 
first to examine the host-pathogen relationship in human microglial cells. It is also the first study to 
show a possible association between neutrophil recruitment and TLR expression in human microglial 
cells. Our hypothesis that the cryptococcal capsular material interfered with neutrophil chemotaxis and 
that the level of chemotaxis inhibition was related to severity of disease was pursued in a 
multicomponent approach. 
A relative paucity of CSF neutrophils in the study cohort was observed, which is consistent with the 
literature. Although the capsule of C. neoformans was not enlarged, we noted an association between 
larger capsule size and lower CSF neutrophil counts in these patients. In addition, a significant 
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association occurred between shed capsular material and CSF neutrophil counts. Lower CSF neutrophil 
counts occurred in patients whose CSF had higher amounts of shed capsular material. These findings 
imply that the capsular components (mainly GXM) do in fact downregulate recruitment of neutrophils 
into the CSF. Chemotaxis inhibition occurred in almost 70% of the isolates tested. This group also had 
a higher amount of shed capsular material in the CSF, which further supports the hypothesis that the 
capsular material interfered with neutrophil chemotaxis.  
There is no known severity of disease score for cryptococcal meningitis, however this study shows that 
chemotaxis inhibition influences clinical parameters. Headache was a predominant finding in all 
patients. Significantly, patients who presented with fever had higher CSF neutrophil counts, which 
suggests that these patients are able to mount an immune response, a finding that has not been explored 
previously. The association between fever and raised CSF neutrophil counts is demonstrated in Figure 
5. These patients also had raised intracranial pressures.  
Figure 5: Summary of Association between Fever and CSF Neutrophils 
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Low capsule shedding [ n = 9 (13%)]    
               
 
 No chemotaxis inhibition [ n = 21 ( 32%)]              
               
 
                                                                         Increased CSF neutrophils [ n = 15 (21%)] 
                                                                                                       
 
                                                                                       Fever  [ n = 15 (21%)]    
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In support of one of our research questions, we showed that downregulation for both TLR2 and TLR4 
occurred in microglial cells exposed to C. neoformans in the majority of isolates. A strong correlation 
between TLR2 and TLR4 gene expression was demonstrated. To further support this, CSF neutrophil 
counts were lower in the group where downregulation of TLR4 occurred.  
This study contributes to understanding the host-immune response to cryptococcal meningitis in 
humans. Our findings address the possible reasons for the paucity of neutrophils in the CSF of 
individuals with cryptococcal meningitis. Further research on a larger study population would be 
valuable to support these findings.  
 
SUMMARY OF THE STUDY LIMITATIONS 
 
The study sample size was smaller than planned initially. During the course of the study, there was a 
general decrease in the number of patients presenting with cryptococcal meningitis, which significantly 
affected patient recruitment. As discussed above, this could possibly be explained by the roll-out of 
HAART in the HIV-infected population. 
A second limitation was that cryptococci were isolated from CSF on sheep blood agar and passaged 
once on BHI plates supplemented with 10% horse blood before capsule measurements were performed. 
Some studies have suggested variations in capsule size when grown in different media with rich media 
resulting in smaller capsules. In this study, all cryptococci were passaged only once on the same media, 
therefore results obtained for each isolate could be compared. 
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APPENDIX A: PROCEDURES 
 
A1. Cell Count: Neubauer Chamber 
 
Neubauer’s chamber is a thick glass plate with the size of a glass slide (30 x 70 x 4 mm). The 
counting region consists of two square shaped ruled areas. There are depressions on either side 
on which the squares are marked, giving it  an “H” shape. The ruled area is 3 mm² and it is 
divided into nine large squares each with an area of 1 mm2. The large central square is divided 
into 25 medium squares with double or triple lines. Each of these 25 squares is  divided into 16 
small squares with single lines, so that each of the smallest squares has an area of 1/400 mm2. 
The coverslip is a square glass 22 mm in width . The glass cover is placed on the top of the 
Neubauer chamber and must cover the central area. The ruled area is 0.1 mm lower than the 
rest of the chamber to allow for a gap of 0.1 mm (1/10 mm) between the cover slip and the 
ruled area. 
 
 
 
 
RBCs are counted in the central large square. Polymorphs and lymphocytes are each counted 
in the four corner squares.  
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Formula: 
Total number of Cells   =                               Number of  Cells      
                                                                   _________________________________                                                                                                                    
                                                                    Depth × Dilution Factor × Area counted 
 
 
 
A2. Gram Staining Principle and Procedure 
 
The Gram stain is a staining method used to differentiate bacteria into two groups (gram 
positive and gram negative). Bacteria stain differentially on the basis of their cell wall 
composition and structure. Gram positive organisms have a thick peptidoglycan layer and are 
not affected by decolourisation, therefore retain the initial stain, appearing deep violet. Gram 
negative organisms have a thinner peptidoglycan layer overlaid by an outer membrane protein 
layer. The outer membrane is damaged by the alcohol decolouriser, allowing the crystal violet-
iodine complex to leak out and be replaced by the counter stain.  
 
             Staining Procedure: 
1. Flood the heat fixed smear (slide) with crystal violet for 30 seconds. 
2. Rinse with running tap water. 
3. Add iodine (which binds to crystal violet and traps it in the cell) and leave for 30 
seconds . 
4. Rapidly decolourise with ethanol or acetone. 
5. Rinse immediately with water. 
6. Counterstain with carbol fuchsin/safranin for 30 seconds 
7. Rinse with water 
8. Drain excess water (blot dry with blotting paper) 
9. Examine smears microscopically (Light microscope) 
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A3. Flow Diagram for Storage of Specimens 
 
 
 
 
 
 
 
 
 
 
 
                    
 
  
      
 
  
         
         
         
         
         
       
 
     
            
            
            
            
            
            
           
            
       
 
  
         
         
         
         
            
            
  
 
      
        
        
                    
Clotted Blood CSF 
Centrifuge at 3000rpm for 5 
minutes 
Remove supernatant and 
store at -80°C 
Culture sediment on Sheep 
Blood agar 
Incubate plate for 48 hours 
at 37°C 
Centrifuge at 3000rpm for 5 
minutes 
Extract serum 
Store at -20°C 
No Growth: Reincubate 
overnight 
Growth: Store in distilled 
water at room temperature 
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A4. Giemsa Staining Procedure (Electron Microscopy Sciences, USA) 
 
1. Place 1.0 mL of the Wright-Giemsa Stain upon the smear, in sufficient quantity to cover the 
entire surface, for 3-4 minutes. 
2. Add 2.0 mL distilled water or Phosphate Buffer, and let stand twice as long as in step 1. 
3. Rinse stained smear with water or the Phosphate Buffer, until the edges show faintly pinkish 
red. 
4. The film is allowed to air dry. The preparation may be blotted gently to hasten drying. 
5. Permanent mounts can be made with mounting medium 
 
 
A5. Reagent Preparation for MPO Human SimpleStep ELISA® Kit (Abcam, Cambridge, UK) 
 
1. 1× Cell Extraction Buffer PTR  
 
Prepare 1× Cell Extraction Buffer PTR by diluting 5× Cell Extraction Buffer PTR and 50× Cell 
Extraction Enhancer Solution to 1× with deionized water. To make 10 mL 1× Cell Extraction 
Buffer PTR combine 7.8 mL deionized water, 2 mL 5× Cell Extraction Buffer PTR and 200 μl 
50× Cell Extraction Enhancer Solution. Mix thoroughly and gently. If required protease 
inhibitors can be added. 
 
2. 1× Wash Buffer PT 
 
Prepare 1× Wash Buffer PT by diluting 10× Wash Buffer PT with deionized water. To make 
50 mL 1× Wash Buffer PT combine 5 mL 10× Wash Buffer PT with 45 mL deionized water. 
Mix thoroughly and gently. 
 
 
 
80 
 
3. Antibody Cocktail 
 
 
Prepare Antibody Cocktail by diluting the capture and detector antibodies in Antibody 
Diluent 4BI. To make 3 mL of the Antibody Cocktail combine 300 μl 10× Capture 
Antibody and 300 μl 10× Detector Antibody with 2.4 mL antibody Diluent 4BI. Mix 
thoroughly and gently. 
 
A6. Standard Preparation for MPO Human SimpleStep ELISA® Kit (Abcam, Cambridge, UK) 
 
The Myeloperoxidase lyophilized standard sample is reconstituted by adding 1mL 1× Cell 
Extraction Buffer PTR by pipette. Mix thoroughly and gently. Keep this at room temperature 
for 10 minutes and mix gently. This is the 5,000 pg/mL Stock Standard Solution. Label eight 
tubes, Standards 1– 8. Add 180 μl 1× Cell Extraction Buffer PTR into tube number 1 and 150 
μl of 1× Cell Extraction Buffer PTR into numbers 2-8. Use the Stock Standard to prepare the  
dilution series. Standard #8 contains no protein and is the Blank control. 
 
A7. Complete Culture Medium (for M059K cells) 
 
Cells are grown in a medium containing a 1:1 mixture of Dulbecco’s Modified Eagle’s Medium 
(DMEM) and Ham’s F12 medium with 2.5 mM L-glutamine adjusted to contain 15 mM 
HEPES, 0.5 mM sodium pyruvate, and 1.2 g/L sodium bicarbonate (Lonza Group Ltd, Basel, 
Switzerland) supplemented with 0.05 mM non-essential amino acids and 10% foetal bovine 
serum. 
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APPENDIX B: MEDIA AND REAGENTS 
 
B1. Sheep Blood Agar 
 
Requirements for 1 litre media: 
1. 40 grams blood agar base (Oxoid Ltd, Cheshire, England)      
2. 1 litre distilled water 
3. 70 mL horse blood (7%) 
4. Petri dishes 
Method:  
1. Suspend 40 g blood agar base (Oxoid Ltd, Cheshire, England) in 1 litre distilled water. 
2. Bring to boil to dissolve completely. 
3. Sterilise by autoclaving at 121°C for 15 minutes.   
4. Remove from autoclave. Place in waterbath at 56.5°C to cool. 
5. Once cooled, remove from waterbath, allow to cool to at least 50°C. 
6. Add 70 mL to 930 mL agar solution and mix gently, without creating bubbles. 
7. Pour immediately into petri dishes at a volume of approximately 18 – 20 mL per petri dish. 
8. Keep at room temperature overnight in sterile environment. 
9. Store prepared plates at 2-8°C until use. 
 
 
B2. Pronase (Meridian Bioscience, Inc, Ohio, USA)  
 
Non-specific protease.  It’s activity extends to both denatured and native proteins leading to complete 
or nearly complete digestion into individual amino acids. 
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B3. Sample Diluent (Meridian Bioscience, Inc, Ohio, USA) 
 
Glycine buffered saline (pH 8.4 ± 0.1) containing bovine serum albumin and 0.01% thimerosal as  
preservative 
 
 
B4. Brain Heart Infusion Agar with Horse Blood 
 
Requirements for 1 litre media ( Approximately 50 plates): 
1. 47 grams BHI agar powder (Oxoid Ltd, Cheshire, England)      
2. 1 litre distilled water 
3. 100 mL horse blood (10%) 
4. Petri dishes 
Method: 
1. Add 47 grams BHI Agar powder (Oxoid, England) in 1 litre distilled water 
2. Autoclave at 121°C for 15 minutes 
3. Remove from autoclave. Place in waterbath (56.5°C) to cool. 
4. Once cooled, remove from water bath, allow to cool to at least 50°C. 
5. Add 100 mL blood to 900 mL agar solution and mix gently, without creating bubbles. 
6. Pour immediately into petri dishes at a volume of approximately 18 – 20 mL per petri dish. 
7. Keep at room temperature overnight in sterile environment. 
8. Store prepared plates at 2-8°C until use. 
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B5. McFarland Turbidity Standard 1 
 
1. Add 0.5 mL of concentrated H₂SO₄ (Merck, Kenilworth, USA) to 49.5 mL of sterilized 
distilled water to make a 1% H₂SO₄ solution 
 
2. Add 0.175 gram of BaCl₂.2H₂O (Sigma-Aldrich, Missouri, USA) to 10 mL of sterilized 
distilled water to make a 1% BaCl₂.2H₂O solution 
 
 For a McFarland Standard of 1.0, mix 0.1 mL of the 1% BaCl₂.2H₂O solution 
with 9.9 mL of the 1% H₂SO₄ solution 
 
3. Cover tube with tin foil and store away from direct sunlight 
 
 
 
B6. Phosphate Buffered Saline 
 
1. Add 10 PBS tablets (Oxoid, England) to 1000 mL distilled water in a 3-litre Erlenmeyer flask 
2. If it is required that bacterial clumping be minimized, add (1%) 10 mL Tween-80 (Merck, SA) 
3. Slowly bring to boil and swirl flask and to mix contents 
4. Sterilize by autoclaving at 121°C for 15 minutes 
5. Cool down at room temperature 
6. Dispense into the required volumes 
7. Store at 4 to 8°C until use 
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B7. Foetal Bovine Serum (FBS) 
 
1. Heat inactivate by de-complementing at 56°C for 1 hour.  
2. Filter sterilize, aliquote into 10 mL tubes and store at -20°C. 
3. Quality control by incubating 5 mL serum at 37°C for one week. Observe for no growth. 
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APPENDIX C: RAW DATA FOR CSF CLAT TITRES, CAPSULE SIZE, 
CHEMOTAXIS INHIBITION AND GENE EXPRESSION 
 
C1. CSF CLAT Titre with Opening pressure, CSF Neutrophils and Capsule size 
i.             CSF CLAT Titre 1 - 512 
Study No Opening 
pressure 
(cmH₂0) 
CSF 
neutrophils 
(cells/mL) 
CSF CLAT 
Titre 
Capsule size 
range (μm) 
Average capsule size 
(μm) 
4   0 256 1.015-1.036 1.025 
6 31 60 128     
9 55 8 256 0.770-1.163 1.017 
10 27 0 2     
15 26 4 512 1.850-3.739 2.457 
18 23 12 4 0.955-1.454 1.961 
19 29 24 2     
20 23 4 512 0.600-1.507 0.952 
26 15 0 256 1.035-1.574 1.325 
27 30 0 256 0.895-1.780 1.328 
28 15 4 16 1.032-1.229 1.132 
33 1 0 32 0.960-1.434 1.233 
40 13 0 512 1.100-1.744 1.445 
44 35 60 256 1.154-1.916 1.391 
45 37 0 16 1.304-2.114 1.989 
46   0 64 1.092-1.515 1.272 
47 32 2 16 0.891-1.430 1.198 
48 30 64 512 0.779-1.232 1.020 
56 <20 10 1 0.828-1.236 1.030 
59 16 0 64     
62 10 0 512     
65 25 54 16 0.894-2.067 1.543 
67 30 0 256 1.059-1.575 1.252 
69 20 2 32 1.306-1.700 1.461 
70 12 8 256 0.841-2.090 1.329 
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ii.            CSF CLAT Titre 1024 - 4096 
Study No Opening 
pressure 
(cmH₂0) 
CSF 
neutrophils 
(cells/mL) 
CSF CLAT 
Titre 
Capsule size 
range (μm) 
Average capsule size 
(μm) 
1 16 6 4096 1.052-2.127 1.495 
2 <10 0 1024 1.368-2.396 1.902 
3 42 0 1024 1.282-1.848 1.526 
5 32 0 1024 0.959-1.613 1.208 
11 26 110 1024 0.567-1.122 0.835 
13 17 0 2048 0.823-1.098 0.958 
14   0 4096 1.313-2.014 1.719 
16 19 0 4096 0.960-2.048 1.526 
17 27,5 2 4096 1.027-1.610 1.210 
21   0 4096 1.464-2.808 1.970 
22 25 0 1024 1.635-3.011 2.209 
23 39 0 2048 1.021-1.225 1.108 
24 22 0 2048 0.684-1.232 0.971 
25 12 0 4096 1.012-1.848 1.379 
29 27 14 1024 0.680-1.764 1.068 
34 24 0 1024 0.764-1.162 1.061 
35 29 2 1024 1.070-1.413 1.254 
41 18 0 4096 0.819-1.572 1.082 
51 7 0 1024 0.846-1.171 0.982 
54 20 0 4096 0.680-1.024 0.860 
55 16 0 4096 0.835-1.426 1.127 
57 17 0 4096 0.714-1.575 1.103 
58 >50 0 4096 0.894-1.307 1.169 
64 25 0 >2650 0.951-1.193 1.037 
71 10 0 2048 1.027-2.051 1.541 
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iii.           CSF CLAT Titre 8192 - >131072 
Study No Opening 
pressure 
(cmH₂0) 
CSF 
neutrophils 
(cells/mL) 
CSF CLAT 
Titre 
Capsule size 
range (μm) 
Average capsule size 
(μm) 
7 31 0 8192 0.410-1.237 0.733 
8   0 8192 0.960-1.308 1.110 
12 45 4 8192 0.708-0.892 0.767 
30   16 32768 0.525-1.654 1.018 
31 24 0 8192 0.814-1.575 1.231 
32 20 6 16384 0.682-1.132 0.882 
36 9 0 8192 1.092-1.501 1.110 
37 8 2 16384 0.818-1.369 1.027 
38 15 0 16384 0.818-1.229 1.027 
39 16 0 16384 0.819-1.780 1.365 
42 27 0 >131072 0.980-1.902 1.319 
43 10 0 8192 0.754-1.358 1.051 
49 28   >131072     
50 16 96 >131072 0.753-1.438 1.061 
52 7 0 32768 0.876-1.368 1.136 
53 >20 0 >131072 0.886-1.213 1.062 
60 20 0 131072 0.910-1.642 1.292 
61 15 0 8192 0.972-1.645 1.289 
63 27 0 8192 0.821-1.309 1.065 
66 20 0 8192 0.985-2.482 1.756 
68 40 0 8192 1.367-2.102 1.643 
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C2. Capsule size with Opening Pressure, CSF Neutrophils, Blood Neutrophils and CSF 
CLAT Titre 
i. Capsule size 0.5 – 1.198 μm 
Study 
No 
Opening 
pressure 
(cmH₂O) 
CSF 
neutrophils 
(cells/mL) 
Blood neutrophils 
(n ×10⁹cells/L)) 
CSF 
CLAT 
Titre 
Capsule size 
range (μm) 
Average 
capsule size 
(μm) 
7 31 0 13.25 8192 0.410-1.237 0.733 
12 45 4 1.93 8192 0.708-0.892 0.767 
11 26 110 6.61 1024 0.567-1.122 0.835 
54 20 0 7.16 4096 0.680-1.024 0.860 
32 20 6 3.8 16384 0.682-1.132 0.882 
20 23 4 4.15 512 0.600-1.507 0.952 
13 17 0 4.46 2048 0.823-1.098 0.958 
24 22 0 2.25 2048 0.684-1.232 0.971 
51 7 0 3.97 1024 0.846-1.171 0.982 
9 55 8 6.1 256 0.770-1.163 1.017 
30   16 3.25 32768 0.525-1.654 1.018 
48 30 64 4.58 512 0.779-1.232 1.020 
4   0 2.31 256 1.015-1.036 1.025 
37 8 2 2.58 16384 0.818-1.369 1.027 
38 15 0 5.39 16384 0.818-1.229 1.027 
56 <20 10 4.11 1 0.828-1.236 1.030 
64 25 0 6.25 >2650 0.951-1.193 1.037 
43 10 0 5.53 8192 0.754-1.358 1.051 
34 24 0 5.29 1024 0.764-1.162 1.061 
50 16 96 2.57 >131072 0.753-1.438 1.061 
53 >20 0   >131072 0.886-1.213 1.062 
63 27 0 4.26 8192 0.821-1.309 1.065 
29 27 14 3.69 1024 0.680-1.764 1.068 
41 18 0 4.33 4096 0.819-1.572 1.082 
57 17 0 4.29 4096 0.714-1.575 1.103 
23 39 0   2048 1.021-1.225 1.108 
8   0   8192 0.960-1.308 1.110 
36 9 0 1.89 8192 1.092-1.501 1.110 
55 16 0   4096 0.835-1.426 1.127 
28 15 4 1.18 16 1.032-1.229 1.132 
52 7 0 3.46 32768 0.876-1.368 1.136 
58 >50 0 6.2 4096 0.894-1.307 1.169 
47 32 2 9.57 16 0.891-1.430 1.198 
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ii. Capsule size >1.198μm 
 
Study 
No 
Opening 
pressure 
(cmH₂O) 
CSF 
neutrophils 
(cells/mL) 
Blood neutrophils 
(n ×10⁹cells/L) 
CSF 
CLAT 
Titre 
Casule size 
range (μm) 
Average 
capsule size 
(μm) 
5 32 0 4.02 1024 0.959-1.613 1.208 
17 27,5 2 2.37 4096 1.027-1.610 1.210 
31 24 0 6.72 8192 0.814-1.575 1.231 
33 1 0 7.88 32 0.960-1.434 1.233 
67 30 0 2.75 256 1.059-1.575 1.252 
35 29 2 4.4 1024 1.070-1.413 1.254 
46   0   64 1.092-1.515 1.272 
61 15 0 7.71 8192 0.972-1.645 1.289 
60 20 0 4.34 131072 0.910-1.642 1.292 
42 27 0 2.15 >131072 0.980-1.902 1.319 
26 15 0 3.54 256 1.035-1.574 1.325 
27 30 0   256 0.895-1.780 1.328 
70 12 8 6.34 256 0.841-2.090 1.329 
39 16 0 7.03 16384 0.819-1.780 1.365 
25 12 0 4.14 4096 1.012-1.848 1.379 
44 35 60 2.46 256 1.154-1.916 1.391 
40 13 0 4.37 512 1.100-1.744 1.445 
69 20 2   32 1.306-1.700 1.461 
1 16 6 0.82 4096 1.052-2.127 1.495 
3 42 0 5.08 1024 1.282-1.848 1.526 
16 19 0 1.31 4096 0.960-2.048 1.526 
71 10 0 4.28 2048 1.027-2.051 1.541 
65 25 54 8.97 16 0.894-2.067 1.543 
68 40 0 1.43 8192 1.367-2.102 1.643 
14   0   4096 1.313-2.014 1.719 
66 20 0 9.95 8192 0.985-2.482 1.756 
2 <10 0 5.05 1024 1.368-2.396 1.902 
18 23 12 3.12 4 0.955-1.454 1.961 
21   0 0.84 4096 1.464-2.808 1.970 
45 37 0 1.97 16 1.304-2.114 1.989 
22 25 0 2.29 1024 1.635-3.011 2.209 
15 26 4 5.16 512 1.850-3.739 2.457 
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C3. Neutrophil Chemotaxis Inhibition data with CSF Neutrophil counts, CSF CLAT Titre 
and Capsule size 
 
i. No Chemotaxis Inhibition 
Study 
No 
CSF 
neutrophils 
(cells/mL) 
CSF 
CLAT 
Titre 
Average 
capsule 
size 
(μm) 
MPO ELISA 
Data (OD = 
450nm) 
      
        Cryptococcus/E 
coli 
combination 
Cryptococcus 
only 
E coli 
only 
Chemotaxis 
inhibition 
21 0 4096 1.970 0.1305 0.053 0.109 -0.00215 
5 0 1024 1.208 0.247 0.070 0.243 -0.004 
25 0 4096 1.379 0.113 0.053 0.109 -0.004 
20 4 512 0.952 0.117 0.068 0.109 -0.008 
23 0 2048 1.108 0.1195 0.056 0.109 -0.0105 
26 0 256 1.325 0.1405 0.072 0.109 -0.0315 
27 0 256 1.328 0.1475 0.062 0.109 -0.0385 
3 0 1024 1.526 0.360 0.065 0.243 -0.117 
4 0 256 1.025 0.386 0.091 0.243 -0.143 
2 0 1024 1.902 0.393 0.063 0.243 -0.15 
24 0 2048 0.971 0.284 0.062 0.109 -0.175 
7 0 8192 0.733 0.464 0.064 0.243 -0.221 
69 2 32 1.461 0.4745 0.103 0.243 -0.2315 
33 0 32 1.233 5.469 5.971 5.237 -0.232 
1 6 4096 1.495 0.5485 0.070 0.243 -0.3055 
40 0 512 1.445 5.561 5.780 5.237 -0.324 
35 2 1024 1.254 5.701 5.389 5.237 -0.464 
31 0 8192 1.231 5.715 5.042 5.237 -0.478 
34 0 1024 1.061 5.7395 5.665 5.237 -0.5025 
39 0 16384 1.365 5.8485 5.910 5.237 -0.6115 
38 0 16384 1.027 5.912 5.671 5.237 -0.675 
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ii. Positive Chemotaxis Inhibition 
Study 
No 
CSF 
neutrophils 
(cells/mL) 
CSF 
CLAT 
Titre 
Average 
capsule 
size (μm) 
MPO ELISA Data (OD = 450nm)  
Cryptococcus/E 
coli combination 
Cryptococcus 
only 
E coli 
only 
Chemotaxis 
inhibition 
22 0 1024 2.209 0.091 0.055 0.109 0.018 
30 16 32768 1.018 0.0715 0.056 0.109 0.0375 
28 4 16 1.132 0.068 0.059 0.109 0.041 
29 14 1024 1.068 0.0645 0.054 0.109 0.0445 
68 0 8192 1.643 1.627 0.122 1.710 0.083 
36 0 8192 1.110 5.1275 6.000 5.237 0.1095 
71 0 2048 1.541 0.0755 0.053 0.243 0.1675 
37 2 16384 1.027 5.061 6.000 5.237 0.176 
48 64 512 1.020 0.066 0.065 0.243 0.177 
58 0 4096 1.169 0.066 0.056 0.243 0.177 
70 8 256 1.329 0.0635 0.053 0.243 0.1795 
9 8 256 1.017 0.0625 0.053 0.243 0.1805 
18 12 4 1.961 0.062 0.058 0.243 0.181 
47 2 16 1.198 0.0605 0.057 0.243 0.1825 
50 96 >131072 1.061 0.0605 0.053 0.243 0.1825 
51 0 1024 0.982 0.0565 0.054 0.243 0.1865 
32 6 16384 0.882 5.0395 5.141 5.237 0.1975 
53 0 >131072 1.062 0.0401 0.072 0.243 0.2029 
46 0 64 1.272 5.7375 5.477 6.000 0.2625 
44 60 256 1.391 5.668 5.031 6.000 0.332 
8 0 8192 1.110 5.6485 4.252 6.000 0.3515 
41 0 4096 1.082 5.5325 4.845 6.000 0.4675 
17 2 4096 1.210 5.4475 4.819 6.000 0.5525 
66 0 8192 1.756 1.0875 0.077 1.710 0.6225 
43 0 8192 1.051 5.3305 5.360 6.000 0.6695 
45 0 16 1.989 5.249 6.000 6.000 0.751 
11 110 1024 0.835 5.1795 4.800 6.000 0.8205 
42 0 >131072 1.319 5.1385 5.132 6.000 0.8615 
14 0 4096 1.719 4.942 4.695 6.000 1.058 
67 0 256 1.252 0.645 0.075 1.710 1.065 
61 0 8192 1.289 0.5755 0.081 1.710 1.1345 
63 0 8192 1.065 0.539 0.092 1.710 1.171 
15 4 512 2.457 4.8085 4.716 6.000 1.1915 
12 4 8192 0.767 4.7935 4.785 6.000 1.2065 
65 54 16 1.543 0.4915 0.099 1.710 1.2185 
54 0 4096 0.860 0.434 0.062 1.710 1.276 
64 0 >2650 1.037 0.4165 0.102 1.710 1.2935 
60 0 131072 1.292 0.352 0.102 1.710 1.358 
55 0 4096 1.127 0.3505 0.083 1.710 1.3595 
13 0 2048 0.958 4.5875 5.091 6.000 1.4125 
57 0 4096 1.103 0.2485 0.072 1.710 1.4615 
56 10 1 1.030 0.190 0.071 1.710 1.52 
52 0 32768 1.136 0.1185 0.065 1.710 1.5915 
16 0 4096 1.526 4.4035 5.059 6.000 1.5965 
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C4. TLR2 and TLR4 Gene Expression with Capsule size, CSF Neutrophils and CSF CLAT Titre 
i. TLR2 Expression with Capsule size, CSF Neutrophils and CSF CLAT Titre 
Study 
No 
18S TLR2 TLR2/18S Average 
Capsule size 
(μm) 
CSF 
neutrophils 
(cells/mL) 
CSF CLAT 
Titre 
17 2 294,964 60,661 0,026432272 1.210 2 4096 
18 2 265,975 93,697 0,041349735 1.961 12 4 
14 1 981,369 92,927 0,046900188 1.719 0 4096 
9 6 154,244 312,673 0,050806008 1.017 8 256 
22 2 100,092 124,734 0,059394704 2.209 0 1024 
25 455,093 27,135 0,059625389 1.379 0 4096 
15 650,646 39,298 0,060397783 2.457 4 512 
7 
16 
713,160 1 016,068 0,060794479 0.733 0 8192 
36 420,346 27,712 0,065925527 1.110 0 8192 
24 2 626,968 175,981 0,066990088 0.971 0 2048 
37 685,151 48,447 0,070710671 1.027 2 16384 
8 2 818,096 205,638 0,072970383 1.110 0 8192 
4 
19 
745,727 1 509,424 0,076443082 1.025 0 256 
16 536,981 47,055 0,087629236 1.526 0 4096 
28 1 948,331 202,018 0,103687608 1.132 4 16 
1 3 690,052 388,610 0,105312901 1.495 6 4096 
11 1 382,593 151,777 0,10977693 0.835 110 1024 
71 546,041 65,906 0,120698172 1.541 0 2048 
27 537,477 71,055 0,132200652 1.328 0 256 
20 1 637,611 219,187 0,133845604 0.952 4 512 
3 946,743 131,188 0,138567397 1.526 0 1024 
12 
24 
245,568 3 371,908 0,139073186 0.767 4 8192 
38 218,612 36,861 0,168614471 1.027 0 16384 
34 124,800 23,025 0,184497434 1.061 0 1024 
2 652,840 127,875 0,195874664 1.902 0 1024 
60 4 316,575 858,120 0,198796512 1.292 0 131072 
21 1 815,927 368,559 0,202958964 1.970 0 4096 
58 99,963 26,062 0,260712545 1.169 0 4096 
39 238,221 62,182 0,261026419 1.365 0 16384 
57 1 710,332 450,786 0,263566623 1.103 0 4096 
42 5 777,510 1 555,493 0,269232438 1.319 0 >131072 
13 2 252,085 642,026 0,285080576 0.958 0 2048 
40 322,352 99,226 0,307819171 1.445 0 512 
30 2 831,050 1 048,441 0,370336553 1.018 16 32768 
32 159,672 65,942 0,412982795 0.882 6 16384 
63 498,928 222,402 0,445760166 1.065 0 8192 
69 146,038 74,622 0,510978429 1.461 2 32 
65 380,572 211,396 0,555467891 1.543 54 16 
41 4 804,269 2 728,569 0,567946778 1.082 0 4096 
68 191,610 150,010 0,782889092 1.643 0 8192 
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44 2 368,476 1 874,138 0,791284363 1.391 60 256 
29 30,195 25,219 0,835215402 1.068 14 1024 
53 272,440 252,851 0,928099114 1.062 0 >131072 
56 41,524 40,743 0,981180815 1.030 10 1 
67 587,515 577,637 0,983185793 1.252 0 256 
51 52,161 68,345 1,310271498 0.982 0 1024 
55 5 059,433 6 946,552 1,372990271 1.127 0 4096 
31 43,820 68,113 1,554383304 1.231 0 8192 
48 52,265 119,380 2,28414244 1.020 64 512 
43 501,151 1 154,218 2,303133241 1.051 0 8192 
66 280,022 702,605 2,509107253 1.756 0 8192 
23 236,879 879,060 3,711001352 1.108 0 2048 
45 40,914 153,671 3,755951138 1.989 0 16 
5 5,841 27,565 4,719394713 1.208 0 1024 
35 983,777 4 929,847 5,01114318 1.254 2 1024 
47 88,278 492,042 5,573766105 1.198 2 16 
46 3,315 32,414 9,778819152 1.272 0 64 
50 36,034 474,061 13,15577383 1.061 96 >131072 
52 3,965 52,571 13,25874626 1.136 0 32768 
54 26,767 397,587 14,85380324 0.860 0 4096 
61 77,637 2 661,790 34,28529245 1.289 0 8192 
33 473,438 21 647,914 45,72492868 1.233 0 32 
64 45,667 2 136,321 46,7801742 1.037 0 >2650 
26 251,322 39 695,664 157,9473017 1.325 0 256 
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ii. TLR4 Expression with Capsule size, CSF Neutrophils and CSF CLAT Titre 
Study 
No 
18S TLR4 TLR4/18S Average 
Capsule size 
(μm) 
CSF 
neutrophils 
(cells/mL) 
CSF CLAT 
Titre 
17 2 294,964 106,345 0,046338 1.210 2 4096 
14 1 981,369 122,941 0,062049 1.719 0 4096 
9 6 154,244 437,227 0,071045 1.017 8 256 
4 19 745,727 1 499,273 0,075929 1.025 0 256 
13 2 252,085 178,796 0,079391 0.958 0 2048 
12 24 245,568 2 214,537 0,091338 0.767 4 8192 
7 16 713,160 1 555,925 0,093096 0.733 0 8192 
22 2 100,092 206,800 0,098472 2.209 0 1024 
8 2 818,096 283,355 0,100549 1.110 0 8192 
24 2 626,968 277,665 0,105698 0.971 0 2048 
1 3 690,052 395,961 0,107305 1.495 6 4096 
15 650,646 70,163 0,107836 2.457 4 512 
28 1 948,331 212,416 0,109025 1.132 4 16 
16 536,981 66,460 0,123767 1.526 0 4096 
3 946,743 122,351 0,129234 1.526 0 1024 
37 685,151 96,414 0,14072 1.027 2 16384 
20 1 637,611 273,631 0,167091 0.952 4 512 
60 4 316,575 770,819 0,178572 1.292 0 131072 
25 455,093 92,539 0,20334 1.379 0 4096 
11 1 382,593 284,593 0,20584 0.835 110 1024 
57 1 710,332 369,721 0,216169 1.103 0 4096 
21 1 815,927 454,140 0,250087 1.970 0 4096 
36 420,346 109,359 0,260164 1.110 0 8192 
18 2 265,975 615,022 0,271416 1.961 12 4 
38 218,612 59,645 0,272834 1.027 0 16384 
27 537,477 149,452 0,278063 1.328 0 256 
30 2 831,050 800,647 0,282809 1.018 16 32768 
42 5 777,510 1 779,079 0,307932 1.319 0 >131072 
65 380,572 118,138 0,310423 1.543 54 16 
41 4 804,269 1 661,625 0,345864 1.082 0 4096 
2 652,840 272,093 0,416784 1.902 0 1024 
40 322,352 142,002 0,44052 1.445 0 512 
39 238,221 110,497 0,463843 1.365 0 16384 
67 587,515 277,476 0,472287 1.252 0 256 
34 124,800 68,884 0,551955 1.061 0 1024 
63 498,928 283,300 0,567817 1.065 0 8192 
44 2 368,476 1 486,484 0,627612 1.391 60 256 
69 146,038 95,009 0,650582 1.461 2 32 
71 546,041 355,259 0,650608 1.541 0 2048 
55 5 059,433 3 793,110 0,749711 1.127 0 4096 
53 272,440 233,399 0,856697 1.062 0 >131072 
68 191,610 177,153 0,924549 1.643 0 8192 
58 99,963 98,001 0,980367 1.169 0 4096 
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31 43,820 50,523 1,152969 1.231 0 8192 
32 159,672 206,113 1,290857 0.882 6 16384 
56 41,524 56,142 1,352031 1.030 10 1 
48 52,265 80,358 1,537522 1.020 64 512 
43 501,151 804,667 1,605639 1.051 0 8192 
51 52,161 129,441 2,481561 0.982 0 1024 
23 236,879 656,257 2,770427 1.108 0 2048 
66 280,022 798,036 2,849905 1.756 0 8192 
29 30,195 92,281 3,056175 1.068 14 1024 
45 40,914 134,885 3,296804 1.989 0 16 
35 983,777 3 457,118 3,514128 1.254 2 1024 
47 88,278 424,330 4,806735 1.198 2 16 
50 36,034 194,437 5,395878 1.061 96 >131072 
5 5,841 34,795 5,957274 1.208 0 1024 
54 26,767 183,914 6,87099 0.860 0 4096 
33 473,438 7 274,291 15,36483 1.233 0 32 
52 3,965 84,838 21,3965 1.136 0 32768 
61 77,637 1 987,636 25,60182 1.289 0 8192 
64 45,667 1 242,781 27,21384 1.037 0 >2650 
46 3,315 127,953 38,60136 1.272 0 64 
26 251,322 12 193,188 48,51616 1.325 0 256 
 
 
